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Glioblastoma	 multiforme	 (GBM)	 is	 the	 most	 common	 and	 aggressive	 primary	 brain	
cancer	in	adults.	Relapse	after	conventional	surgery	and	chemo/radiotherapy	is	thought	
to	 be	 driven	 by	 glioblastoma	 stem	 cells	 (GSCs).	 GSCs	 have	 phenotypic	 similarities	 to	
normal	 neural	 stem	 cells	 (NSCs)	 and	 frequently	 overexpress	 many	 key	
neurodevelopmental	 transcription	 factors,	 including	 FOXG1,	 a	 key	 forebrain	










regulator	 of	 promoter	 activation,	 is	 thought	 to	 be	 a	 protein	 partner	 of	 FOXG1.	 We	




















caused	by	 cells	 called	 ‘glioblastoma	 stem	cells’	 (GSCs),	which	share	many	 similarities	
with	normal	brain	stem	cells.	In	development,	brain	stem	cells	are	tightly	controlled	by	
molecules	called	transcription	factors;	these	determine	when	certain	genes	are	switched	







and	 by	 modifying	 genes	 in	 these	 cells	 using	 the	 latest	 genetic	 engineering	 tool,	
CRISPR/Cas9.	
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knowledge	 of	 GBM	molecular	 and	 cellular	 biology;	 2)	 The	 role	 of	 master	 regulatory	
transcription	 factors	 in	 NSC	 biology,	 cellular	 reprogramming	 and	 cancers,	 including	
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1.1 The molecular and cellular aetiology of GBM 
1.1.1 Diagnosis and current treatments for GBM 
Gliomas	are	a	type	of	tumour	that	arise	in	the	brain	or	spinal	cord.	They	are	categorised	
according	 to	 the	World	Health	 Organisation	 classification	 system	 (Louis	 et	 al,	 2016)	
based	 on	 microscopic	 morphology,	 immunohistochemistry	 and	 recently	 added	
molecular	 features	 (Aldape	 et	 al,	 2019).	 Based	 on	 this	 classification,	 gliomas	 can	 be	
















months	 (Tykocki	 &	 Eltayeb,	 2018;	 Stupp	 et	 al,	 2010;	 National	 Cancer	 Intelligence	
Network,	2013),	GBM	accounts	for	more	years	of	active	life	lost	than	any	other	cancer.	
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Following	 surgery,	 sensitivity	 to	 TMZ	 can	 be	 predicted,	 albeit	 quite	 poorly,	 using	 an	
MGMT	 promoter	 methylation	 test	 (Hegi	 et	 al,	 2005).	 The	MGMT	 gene	 encodes	 the	
enzyme	O6-methylguanine–DNA	methyltransferase,	that	repairs	DNA	damage	caused	by	








are	 limited	 in	 their	 effectiveness	 and	 result	 in	 significant	 tissue	 toxicities	 and	 poor	
quality	of	life.	There	are	emerging	treatments,	such	as	Tumour	Treating	Fields,	in	which	





approaches	 are	 therefore	 needed	which	 better	 consider	 the	 biology	 of	 GBM	 and	 the	
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underlying	mechanisms	of	 its	 initiation	and	maintenance	 in	order	 to	prevent	patient	
relapse.	 As	 we	 will	 discuss	 in	 the	 next	 section,	 the	 inter-	 and	 intra-tumoural	
heterogeneity	 found	 in	 GBMs,	 at	 the	 genetic,	 epigenetic	 and	 cellular	 levels,	 presents	
challenges	to	the	development	of	targeted	therapeutics.	
1.1.2 GBM genetics 
GBMs	are	 intrinsically	heterogeneous.	 Indeed,	 as	 the	name	 ‘glioblastoma	multiforme’	
implies,	this	is	a	complex	disease	that	takes	multiple	forms.	This	is	especially	apparent	
with	regards	to	the	genetic	profile	of	GBMs.	The	extensive	genetic	landscape	of	GBMs	




patient	 samples	 to	 reveal	 a	 common	 set	 of	 pathways	 disrupted,	 including	 aberrant	
activation	of	oncogenes,	such	as	EGFR	and	Akt,	and	disruption	of	tumour	suppressors,	
such	as	p53,	PTEN	and	pRb.	These	frequent	genetic	alternations	fall	 into	three	critical	
signalling	 pathways:	 the	 RB,	 Tp53	 and	 RTK	 pathways.	 ~74%	 of	 GBMs	 harbour	
disruptions	 to	 all	 three.	 This	 suggested	 that	 deregulation	 of	 these	 core	 signalling	
pathways	is	a	key	driver	of	GBM	pathogenesis	and	may	aid	therapeutic	decisions	(Figure	
1-1	A).	
Several	 studies	have	 shown	that	GBMs	 can	be	molecularly	 classified	 into	 two	 to	 four	
major	groups	(Verhaak	et	al,	2010;	Phillips	et	al,	2006;	Huse	et	al,	2011;	Brennan	et	al,	
2009;	Park	et	 al,	 2019).	Based	on	TCGA	GBM	gene	 expression	profiles,	Verhaak	et	 al	
described	four	transcriptional	subtypes:	Proneural,	Classical,	Mesenchymal	and	Neural,	
each	associated	with	a	set	of	common	genetic	aberrations	(Verhaak	et	al,	2010).	Later	










unclear.	 Receptor	 tyrosine	 kinases	 (RTKs)	 such	 as	 epidermal	 growth	 factor	 receptor	
(EGFR),	platelet-derived	growth	factor	receptor	a/b	(PDGFR	a/b)	and	the	hepatocyte	
growth	 factor	 receptor	 MET	 are	 frequently	 activated	 in	 GBMs.	 EGFR	 mutations	 and	
amplifications	 are	 found	 in	 45-57%	 of	 GBM	 cases	 (Brennan	 et	 al,	 2013;	 The	 Cancer	
Genome	 Atlas	 Research	 Network,	 2008;	 Pearson	 &	 Regad,	 2017)	 with	 a	 truncated,	
constitutively	active	form,	EGFR	variant	III	(EGFRvIII),	frequently	expressed.	Numerous	
kinase	inhibitors	and	antibody	therapies	have	been	trialled	clinically	(Lee	et	al,	2015;	
van	Den	 Bent	 et	 al,	 2009;	 Jane	 et	 al,	 2009;	 Sampson	 et	 al,	 2011;	 Neyns	 et	 al,	 2009),	
however	 none	 have	 given	 clear	 consistent	 benefits.	While	 ongoing	 research	 is	 being	





all	 GBMs.	 Success	 may	 require	 combinatorial	 targeting	 of	 multiple	 pathways	 with	
increased	 risks	 of	 deleterious	 side	 effects,	 or	 the	 identification	 of	 new	 biological	
vulnerabilities.	









alteration	 and	 the	 percentage	 of	 tumours	 possessing	 this	 genetic	 aberration	 are	 noted	
underneath	each	pathway	component.	Highlighted	boxes	show	the	percentage	of	GBMs	with	a	
genetic	 alternation	 in	at	 least	 one	component	 of	 the	 described	pathway.	Figure	adapted	with	
permission	from	Macmillan	Publishers	Ltd:	Nature,	(The	Cancer	Genome	Atlas	Research	Network,	
2008).	(B)	Molecular	classification	of	GBMs	based	on	their	genomic	profiles.	Subtypes	described	
by	 (Verhaak	et	 al,	 2010;	Wang	 et	 al,	 2017b).	 Subtypes	are	 shown	 alongside	common	 genetic	
features	and	the	predominant	expression	signature,	determined	by	Verhaak	et	al	by	comparison	
with	gene	sets	defined	using	the	brain	transcriptome	database	presented	by	(Cahoy	et	al,	2008).		















subtype	 (Wang	 et	 al,	 2017b;	 Sidaway,	 2017).	 While	 GBM	 relapse	 was	 previously	
associated	with	progression	 from	a	proneural	 to	mesenchymal	 subtype,	more	 recent	
studies	have	not	validated	this	association,	suggesting	there	 is	no	common	pattern	 to	
shifts	in	genetic	and	transcriptional	subtypes	(Phillips	et	al,	2006;	Ozawa	et	al,	2014).	
Transcriptional	 subtypes	 have	 been	 shown	 to	 correlate	 with	 the	 immune	 response	
(Wang	 et	 al,	 2017b);	 changes	 in	 the	 tumour	 microenvironment	 may	 therefore	 also	
promote	transcriptomic	adaptability	of	tumour	cells	leading	to	clonal	evolution	(Olar	&	





these	 signatures	 for	 therapeutic	use.	 It	 is	 possible	 that	with	 time	and	 changes	 in	 the	
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1.1.3 The cellular origin of glioblastoma 
The	 finding	 that	 GBMs	 can	 be	 classified	 into	 molecular	 subtypes	 also	 raised	 new	
questions	 regarding	 their	 cell	 of	 origin.	 This	 is	 defined	 as	 the	 cell	 type	 in	which	 the	
transforming	mutations	that	lead	to	gliomagenesis	first	occur,	and	has	been	subject	to	
controversy	for	many	years.	To	understand	the	possible	cells	of	origin	in	GBM	we	must	




hippocampal	 denate	 gyrus	 (DG)	 (Alvarez-Buylla	 et	 al,	 2002;	Modrek,	 2014;	 Braun	&	
Jessberger,	2014;	Doetsch	et	al,	1999;	Gage,	2000;	Kriegstein	&	Alvarez-Buylla,	2009).	






which	migrate	 to	 the	olfactory	bulb	 to	become	neurons	 (Modrek,	 2014;	Kriegstein	&	
Alvarez-Buylla,	2009).	Various	immature	stem	and	precursor	cell	types	therefore	exist	
with	different	lineage-restrictions	and	proliferative	capacities	(Figure	1-2	A).	















factors,	 EGF	 and	 FGF-2,	 and	 differentiation	 cues	 such	 as	 BMP4.	 For	 simplicity,	 changes	 in	
morphology	are	not	depicted.	Figure	made	using	BioRender.	
Chapter 1 | Introduction 
 
 10 




samples	 was	 recently	 acquired	 through	 deep	 sequencing	 and	 genetic	 comparison	 of	
matched	normal	SVZ,	 tumour	and	normal	cortical	tissues	(Lee	et	al,	2018).	However,	
NSCs	in	vivo	can	exist	in	both	active	proliferating	states	and	non-cycling	quiescent	states	







Differentiated	 cell	 types	 and	 their	 precursors	 have	 also	 been	 shown	 to	 have	 some	
proliferative	capacity,	 suggesting	 they	could	also	be	at	risk	of	acquiring	 transforming	
mutations	 (Zong	 et	 al,	 2015).	 For	 example,	 oligodendrocyte	 precursor	 cells	 (OPCs)	
continue	dividing	into	adulthood	and	can	outnumber	NSCs	in	the	adult	brain	in	humans	
and	 rodents	 (Dawson	 et	 al,	 2003;	 Dimou	 et	 al,	 2008).	 Histopathological	 analysis	 has	
revealed	OPC	marker	expression	in	human	GBM	samples	(Shoshan	et	al,	2002;	Lu	et	al,	
2001;	 Ligon	et	 al,	 2004;	Rebetz	et	 al,	 2008)	and	overexpression	of	 the	OPC	mitogen,	
PDGF,	 in	 the	 brain	 of	mice	 resulted	 in	 the	 formation	 of	 tumours	 expressing	 the	 OPC	
markers,	 PDGFRa	 and	 NG2	 (Assanah	 et	 al,	 2006).	 Furthermore,	 loss	 of	 the	 tumour	
suppressors	p53	(encoded	by	Trp53)	and	Nf1	in	NSCs	resulted	in	tumour	growth	driven	
by	the	expansion	of	OPCs	but	not	other	NSC-derived	lineages	or	NSCs	themselves	(Liu	et	











and	 are	 therefore	 a	 potential	 cell	 of	 origin.	 However,	 experimental	 conditions	 that	
artificially	 enforce	 certain	 genetic	 events	 do	 not	 signify	 that	 this	 occurs	 during	 the	
aetiology	of	GBM	in	vivo.		
The	 intrinsic	 properties	 of	 different	 cell	 types	 may	 determine	 vastly	 different	
susceptibilities	 to	 be	 the	 cell	 of	 origin.	 Recently,	 assessment	 of	 the	 tumour-initiating	
potential	 of	 adult	 neural	 progenitor	 cells	 at	 various	 stages	 of	 lineage	 progression	
revealed	 a	 ‘glioblastoma	 cell-of-origin	 hierarchy’,	 in	 which	 there	 is	 decreasing	
susceptibility	to	transformation	with	increasing	lineage	restriction	(Alcantara	Llaguno	
et	 al,	 2019).	The	 revelation	 that	GBMs	 can	be	 grouped	 into	different	subclasses	with	
common	genetic	 aberrations	has	also	hinted	 at	 a	difference	 in	 cell	 of	 origin	between	
subgroups	 (Verhaak	et	 al,	 2010);	 for	 example	 the	molecular	 profile	 of	 the	 proneural	
subtype	of	GBM	closely	matched	an	OPC	profile.	This	suggests	that	although	some	cell	
types	are	more	prone	 to	malignant	 transformation,	patient	 tumours	could	arise	 from	
diverse	 cells	 of	 origin.	 However,	 given	 the	 evidence	 for	 heterogeneity	 and	 genetic	
plasticity	 within	 tumours,	 it	 is	 also	 possible	 that	 the	 predominant	 features	 of	 an	
established	tumour	do	not	necessarily	reflect	those	of	the	cell	from	which	it	originated.	
The	cell	of	origin	of	GBM	is	therefore	difficult	to	prove.		
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1.2 Glioblastoma and the cancer stem cell hypothesis 
A	separate	question	to	where	and	when	GBMs	first	arise	through	their	cell	of	origin,	is	




1.2.1 The cancer stem cell hypothesis 








which	 endow	 them	with	malignant	 properties,	 and	 tumour-propagating	 cells	 do	 not	
share	a	biological	uniqueness	enabling	their	 isolation.	The	selection	and	expansion	of	





Conversely,	 the	 CSC	 hypothesis	 postulates	 that	 tumour	 formation	 and	 long-term	




namely,	 the	 ability	 to	 self-renew	 and	 to	 give	 rise	 to	 differentiated,	 non-malignant	
progeny	 (Clarke	et	 al,	 2006;	 Sell,	 2010;	Reya	et	 al,	 2001)	 (Figure	1-3	B).	Given	 their	
biological	 uniqueness,	 it	 must	 therefore	 be	 possible	 to	 isolate	 CSCs	 based	 on	 their	
intrinsic	properties.	In	this	model,	the	tumour	is	organised	in	a	differentiation	hierarchy	
reminiscent	 of	 that	 in	normal	 tissues	 containing	 tissue	 stem	cells;	 however,	 aberrant	
control	of	this	hierarchy	results	in	tumour	formation.	A	population	of	CSCs	is	maintained	
at	 the	 apex,	 which	 gives	 rise	 to	 differentiated	 tumour	 cell	 progeny	 of	 decreasing	
proliferative	capacity	and	increasing	specialisation.	The	CSC	is	therefore	responsible	for	
propagating	tumour	growth	and	is	the	therapeutic	target.		 	




Figure	1-3	 |	Two	predominant	models	exist	 to	explain	 the	heterogeneity	and	continued	
propagation	of	cancer.		
(A)	The	clonal	evolution	model	suggests	that	all	cells	within	the	tumour	have	equal	potential	to	
gain	 malignant	 properties,	 through	 exposure	 to	 intrinsic	 and	 extrinsic	 influences,	 and	 drive	


















characterised	 by	 their	 expression	 levels	 of	 the	 cell	 surface	markers	 CD34	 and	 CD38	
(Lapidot	et	al,	1994).	While	work	in	the	haematopoietic	system	is	most	advanced	with	
respect	 to	 the	 identification	 and	 characterisation	 of	 CSCs,	 there	 is	 now	 mounting	
evidence	that	CSCs	exist	in	several	types	of	solid	tumour	(Visvader	&	Lindeman,	2008).	
For	example,	Al-Hajj	and	colleagues	were	 the	 first	to	 isolate	a	 fraction	of	 tumorigenic	
cells	in	human	breast	carcinoma	(Al-Hajj	et	al,	2003).		
1.2.2 The discovery of CSCs in GBM 






cells	 can	 give	 rise	 to	heterogeneous	 tumours	 that	 are	 serially	 transplantable	 and	are	
reminiscent	 of	 neural	 progenitors,	 upregulating	 neuronal	 and	 glial	 marker	 protein	
expression	on	exposure	to	serum	(Hemmati	et	al,	2003;	Stiles	&	Rowitch,	2008).	These	
identified	glioblastoma	stem	cells	(GSCs)	are	defined	as	a	tumour	sub-population	that	
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al,	 2009).	These	 cells	 also	display	many	NS	 cell	properties,	 such	 as	high	motility	and	
expression	 of	 the	 neural	 progenitor	 markers	 Sox2	 and	 Nestin,	 and	 hence	 they	 are	
referred	 to	 as	 glioblastoma	 NS	 (GNS)	 cells.	 The	 advantages	 of	 this	 culture	 system	
compared	to	conventional	glioma	cell	lines	is	described	further	in	section	1.5.2.		
In	 addition,	 Pollard	 et	 al	 found	 GNS	 cell	 lines	 from	 different	 patients	 could	 be	
distinguished	based	on	their	expression	of	lineage-specific	neural	progenitor	markers,	
mirroring	 some	 of	 the	 differences	 in	 transcriptional	 subtypes	 described	 previously	








Furthermore,	 it	 is	 increasingly	 clear	 that	 the	 hierarchical	 CSC	 and	 stochastic	 clonal	
evolution	models	of	tumour	heterogeneity	are	not	mutually	exclusive.	Recently	a	third	
‘unified’	dynamic	model	has	been	suggested	(Kreso	&	Dick,	2014;	Corrò	&	Moch,	2018;	
Rich,	2016)	(Figure	1-4	A).	This	considers	that	 in	 the	course	of	 tumour	development,	
tumour	cells	may	be	exposed	to	influences,	such	as	genetic	mutations,	that	alter	their	
behaviour.	 This	 could	 lead	 to	 phenotypic	 plasticity,	 with	 the	 formation	 of	 new	 CSC	
branches	or	the	conversion	of	differentiated	cells	to	a	stem	cell	phenotype.	As	a	result,	
multiple	CSC	clones,	each	competing	and	giving	rise	to	their	own	hierarchy,	may	coexist	
within	 a	 tumour.	 Furthermore,	 the	 ‘depth’	 of	 tumour	developmental	 hierarchies	may	
alter	during	 tumour	progression	(Figure	1-4	B).	While	CSCs	may	 initially	exist	at	 low	
frequencies	 in	 the	 tumour,	 their	 numbers	 may	 expand	 in	 response	 to	 accumulative	
malignant	properties,	 leading	to	sub-clones	with	higher	 frequencies	of	stem-like	cells	
(Kreso	 &	 Dick,	 2014).	 These	 processes	 may	 be	 accelerated	 by	 changes	 in	 the	
microenvironment	and	could	explain	the	change	in	predominant	transcriptional	subtype	
often	 found	on	 tumour	recurrence.	The	extent	 to	which	 this	unified	 ‘plasticity’	model	
applies	to	GSCs	is	as	yet	unclear.	A	recent	fate	mapping	study	of	barcoded	GSCs	following	
xenotransplantation	 found	 that	 the	 majority	 of	 clones	 showed	 hierarchical	 growth,	
neutral	 to	 evolving	mutations;	 however,	 a	minority	 subset	were	 expanded	after	TMZ	
treatment	 (Lan	et	al,	2017).	Nevertheless,	despite	potential	 inter-	and	 intra-tumoural	
differences	in	GSC	clones,	all	possess	the	same	NSC-like	characteristics.	





(A)	 The	 unified	 ‘plasticity’	 model	 suggests	 that,	 over	 time,	 tumour	 cells	 will	 be	 exposed	 to	
influences	 that	 change	 their	 behaviour.	 For	 example,	 CSCs	 may	 themselves	 undergo	 clonal	
evolution,	 or	 differentiated	 cells	 may	 acquire	 stem	 cell	 characteristics	 in	 response	 to	
environmental	 pressures	 such	 as	 treatments.	 This	 leads	 to	 competing	 CSC	 clones	 within	 an	
individual	 tumour	 (Kreso	 &	 Dick,	 2014;	 Rich,	 2016).	 (B)	 Over	 time	 the	 depth	 of	 tumour	
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1.2.3 Challenges posed by GSCs for the treatment of GBM 







cells,	 resulting	 in	 resistance	 to	potential	 differentiation	 therapies	(Carén	et	 al,	2015).	
Furthermore,	like	normal	adult	NSCs	in	vivo	and	in	vitro,	it	is	likely	that	GSCs	can	adopt	a	
continuum	of	 states,	 from	dormancy	 to	 active	proliferation	 (Figure	1-2	B).	Quiescent	




In	 conclusion,	 despite	 controversy	 surrounding	 the	 cell	 of	 origin	of	GBM,	 it	 is	widely	





eliminate	 the	 tumour	 bulk.	 This	 requires	 an	 understanding	 of	 the	 transcriptional	
networks	 that	 limit	 the	 differentiation	 of	 GSCs	 and	 underpin	 their	 self-renewal,	 and	
hence	drive	their	initiation	and	maintenance.	
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1.3 Transcription factors and reprogramming in cancer  
1.3.1 Transcription factors control gene expression to determine cell identity  
There	are	~20,000	protein-coding	genes	in	the	human	genome,	whose	expression	levels	
must	 be	 tightly	 regulated,	 temporally	 and	 spatially,	 to	 give	 rise	 to	 the	 abundance	 of	
different	cell	identities	found	in	the	body.	Cell	type	identity	is	governed	by	the	action	of	
transcription	 factors,	 proteins	 that	 bind	 to	 DNA-regulatory	 sequences,	 often	 in	
combination,	to	control	the	rate	of	transcription.		Transcription	factors	(TFs)	belong	to	
two	main	classes:	 i)	general	TFs,	which	together	with	the	RNA	polymerases,	form	the	




domains	 and	 trans-activation	 or	 trans-repression	 effector	 domains.	 Many	 sequence-
specific	TFs	are	expressed	in	a	lineage-	or	cell	type-specific	manner.	
TFs	can	lead	to	repression	or	activation	of	specific	genes	by	several	mechanisms.	Some	
directly	 recruit	 RNA	 polymerase,	 while	 others	 recruit	 accessory	 factors	 to	 promote	
specific	 phases	 of	 transcription	 (Frietze	 and	 Farnham,	 2011;	 Lambert	 et	 al,	 2018b).	
However,	most	eukaryotic	TFs	act	by	recruiting	either	co-repressors	or	co-activators,	
often	 as	multi-subunit	 complexes.	 These	 often	 contain	 enzymatic	 activities,	 enabling	
covalent	modification	 of	 TFs	 and	 RNA	 polymerases	 themselves,	 as	 well	 as	 DNA	 and	
histones,	leading	to	chromatin	remodelling	and	changes	in	DNA	accessibility.	In	this	way,	
TF	 binding	 to	 DNA	 can	 lead	 to	 changes	 in	 the	 epigenetic	 landscape	 that	 facilitate	 or	
repress	 transcription	 initiation.	 In	 addition,	 some	TFs	 themselves	 can	 act	 as	 pioneer	
factors,	binding	to	and	derepressing	closed	chromatin,	directly	leading	to	increased	DNA	









(Rosenfeld	 et	 al,	 2006)	 and	 the	 local	 DNA	 sequence	 context	 (Meijsing	 et	 al,	 2009;	
Lambert	et	al,	2018b;	Seth	&	Majzoub,	2001).	Most	likely	there	is	a	network	of	TF	and	
cofactor	 interactions	 that	 result	 in	 gene	 expression	 changes	 in	 a	 context-dependent	
manner,	 to	ensure	correct	progenitor	proliferation	and	cellular	differentiation	during	
development	(Lambert	et	al,	2018b).		
1.3.2  Master transcription factors can lead to cell fate conversions 
TFs	whose	expression	is	limited	to	a	particular	tissue	or	cellular	lineage	are	described	as	
lineage-specific	(Kumar	et	al,	2019).	Several	examples	of	such	TFs	have	been	reported	
such	 as	MYOD,	which	 establishes	muscle	 development	 (Fong	&	 Tapscott,	 2014),	 and	
PAX5,	which	is	essential	for	B	cell	lymphogenesis	(Morrison	et	al,	1998).	The	interaction	
of	a	precise	combination	of	these	factors	results	in	an,	often	autoregulatory	and	self-re-
enforcing,	 TF	 network	 that	 leads	 to	 cell-type	 specific	 expression	 patterns	 and	 hence	
lineage	specification	(Bottardi	et	al,	2007).		
Over	 the	 last	 twenty	 years,	 several	 seminal	 studies	have	 shown	 the	 ability	 of	 sets	 of	
lineage-specific	TFs	to	reprogramme	cell	lineages.	As	such,	they	are	often	termed	‘master	
regulatory’	 TFs	 as	 their	 potent	 function	 suggests	 they	 lie	 at	 the	 top	 of	 a	 regulatory	
network.	In	1978,	Davis	et	al.	first	observed	that	MyoD	alone	could	drive	the	conversion	
of	 fibroblasts	 into	myoblasts	 (Davis	 et	 al,	 1987).	Over	 25	 years	 later,	 Yamanaka	 and	






1.3.3 Epigenetic resetting is facilitated by master regulators 
Research	into	understanding	how	these	master	regulators	interact	with	the	genome	and	
other	molecules	to	drive	these	cell	fate	conversions	is	of	great	interest	(Soufi,	2014;	Fong	
&	 Tapscott,	 2013;	 Apostolou	 &	 Stadtfeld,	 2018).	 Importantly,	 they	 must	 reset	 the	
transcriptional	programme	to	that	of	the	new	cell	state	(Hochedlinger	&	Plath,	2009).	To	
do	 this,	 global	 and	 focal	 changes	 in	 reversible	 histone	 modifications	 and	 DNA	
methylation,	collectively	known	as	‘epigenetic	resetting’,	must	occur	(Suvà	et	al,	2013;	
Orkin	 &	 Hochedlinger,	 2011).	 This	 in	 turn	 overcomes	 DNA	 accessibility	 barriers	 to	
facilitate	changes	in	gene	expression.	In	the	formation	of	iPSCs,	genome-wide	profiling	
of	 TF	 binding,	 chromatin	 state	 and	 DNA	 methylation	 patterns	 reveals	 significant	




Pollard,	 2014).	 This	 is	 facilitated	 by	 a	 set	 of	 DNA	methyltransferase	 enzymes,	which	
catalyse	 both	 de	 novo	 DNA	 methylation	 (DNMT3a	 and	 b)	 and	 maintenance	 of	
methylation	 (DNMT1)	 (Xu	 et	 al,	 2010;	 Romani	 et	 al,	 2018),	 and	 TET	methylcytosine	
dioxygenases	(TET1/2/3),	which	convert	5-methylcytosine	to	5-hydroxymethlycytosine	
to	initiate	a	demethylation	process.		
Initially	 DNA	 methylation	 was	 considered	 generically	 transcriptionally	 repressive;	
methylation	 at	 CpG	 islands	 in	 gene	 promoters	 generally	 correlates	 inversely	 with	






transcriptional	 change	 cannot	 always	 be	 easily	 predicted	 (Stricker	 &	 Pollard,	 2014).	
Nevertheless,	 global	 changes	 in	 DNA	 methylation	 marks	 are	 a	 key	 barrier	 to	 the	
transition	to	a	stem	cell	state,	acting	to	modify	the	interactions	of	DNA	with	specific	TFs	










packaging.	 This	 chromatin	 structure	 is	 altered	 by	 a	 series	 of	 post-translational	
modifications	 present	 on	 the	 tails	 of	 the	 histone	 proteins	 around	 which	 DNA	 is	
structured.	More	than	100	histone-modifying	enzymes	act	together	to	‘write’	and	‘erase’	














by	 multi-subunit	 protein	 complexes,	 such	 as	 the	 nucleosome	 remodelling	 and	
deacetylase	 (NuRD)	 complex	 (Basta	 &	 Rauchman,	 2009),	 polycomb	 repressive	
complexes	(PRCs)	(Chittock	et	al,	2017)	and	the	SWI/SNF	complex	(Lu	&	Allis,	2017),	
which	 function	 in	 equilibrium	 to	 stabilise	 and	 maintain	 gene	 expression	 patterns	
(Bracken	et	al,	2019).		
1.3.4 The link between reprogramming and tumorigenesis  
In	addition	to	the	transformative	applications	that	reprogramming	research	has	had	on	
disease	 modelling	 and	 cell	 therapies,	 it	 also	 demonstrates	 the	 ability	 of	 master	
regulatory	 TFs	 to	 drive	 a	 complete	 conversion	 of	 cell	 fate	 in	 inappropriate	
developmental	contexts	(Suvà	et	al,	2013).	The	conceptual	and	mechanistic	similarities	
between	 in	 vitro	 reprogramming	and	tumour	development	have	become	 increasingly	
apparent,	with	the	expression	of	master	regulatory	lineage-specific	TFs	playing	a	vital	
role	 in	 emergence	 of	 a	 stem	 cell-like	 phenotype	 in	 both	 cases.	 Cells	 that	 undergo	
malignant	transformation	enter	an	immature	state	and	acquire	self-renewal	capacity	to	
drive	 tumour	 formation.	 Furthermore,	 there	 are	 numerous	 examples	 of	 TFs	 and	
chromatin	 regulators	 that	 have	 established	 roles	 in	 both	 cancer	 and	 iPSC	
reprogramming	 (Suvà	 et	 al,	 2013).	 For	 example,	 c-Myc	 and	 the	 developmental	
transcription	factor,	SOX2,	both	components	of	the	OKSM	reprogramming	cocktail,	have	
a	wide	range	of	functions	in	human	cancers.	The	transcriptional	networks	that	normally	






1.3.5 Master regulatory transcriptional networks in glioblastoma stem cells 
The	finding	that	CSCs	rely	on	many	of	the	signalling	pathways	required	for	maintenance	
of	the	stem	cell	state	can	be	extended	to	GSCs	(Jackson	et	al,	2014;	Guo	et	al,	2011).	As	
described	 in	 section	 1.2.2,	 GNS	 cells	 were	 found	 to	 possess	 NS	 cell-like	 properties,	
including	 the	 expression	of	 several	 key	NSC	markers	 (e.g.	Nestin,	Ascl1,	 Sox2,	Olig2),	
suggesting	 factors	 involved	 in	 controlling	 normal	 NSCs	 may	 be	 important	 to	 GSC	
initiation	 and	 maintenance.	 Indeed,	 several	 studies	 have	 found	 transcriptional	
regulators,	 normally	 kept	 in	 check	 by	 PRCs,	 to	 have	 increased	 activation	 in	 glioma-
initiating	cells	(Singh	et	al,	2017;	Rheinbay	et	al,	2013;	Bulstrode	et	al,	2017;	Garcia	et	al,	





factors	 (POU3F2,	 SOX2,	 SALL2	 and	 OLIG2)	 that	 are	 sufficient	 to	 reprogramme	
differentiated	GBM	cells	into	stem-like	tumour	propagating	cells	(Suvà	et	al,	2014).	The	
coordinated	induction	of	three	core	transcription	factors	(Sox2,	Olig2	and	Zeb1)	was	also	
recently	 shown	 to	 transform	 immortalised	 astrocytes	 without	 oncogene	 induction	
(Singh	et	al,	2017).	Furthermore,	a	recent	genome-wide	CRISPR/Cas9	screen	identified	
key	 ‘stemness	 regulators’	 in	 GSCs,	 including	 SOX2	 and	 SOX9	 (MacLeod	 et	 al,	 2019).		
These	 factors	 have	 important	 known	 roles	 in	 lineage	 restriction	 during	 neural	








Notably,	 in	 addition	 to	 their	 developmental	 roles,	 several	 of	 these	 factors	 have	 been	
shown	to	possess	reprogramming	activity	in	vitro	(Pang	et	al,	2011;	Lujan	et	al,	2012).	








Caren	 et	 al	 found	 that	 GNS	 cell	 lines	 are	 unable	 to	 respond	 appropriately	 to	 the	
differentiation	signal	BMP4,	known	to	trigger	cell	cycle	exit	and	astrocyte	differentiation	
of	 NSCs	 (Carén	 et	 al,	 2015;	 Bonaguidi,	 2005);	 chromatin	 accessibility	 revealed	 that	
regions	 that	 failed	 to	 close	 on	 BMP4	 treatment	 were	 enriched	 in	 SOX2	 motifs.	 This	
suggests	that	the	elevated	levels	of	master	regulators,	such	as	SOX2,	found	in	GSCs	may	
facilitate	 their	ability	to	evade	differentiation	and	maintain	a	stem	cell-like	state.	 It	 is	
likely	 that	 the	high	 levels	 of	master	 regulators	 in	GSCs	are	 constantly	acting	 to	drive	
cellular	 reprogramming	 in	 the	presence	of	 changing	 environmental	 challenges	 to	 the	
stem	cell	state.	How	these	master	regulatory	TFs	are	able	to	control	the	GSC	state,	leading	
to	dysregulated	self-renewal,	is	a	question	of	great	interest.	
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shown	 to	 have	 aberrations	 in	 a	 chromatin	 modifier	 gene	 (Brennan	 et	 al,	 2013;	
Bruggeman	et	al,	2007;	Lee	et	al,	2008;	Azzarelli	et	al,	2018).	In	addition	to	direct	genetic	













GBM	 iPSCs	 (GiPSCs)	 using	 exogenous	 expression	of	OCT4	 and	KLF4.	 This	 resulted	 in	
resetting	 of	 DNA	 methylation	 marks;	 however	 this	 was	 insufficient	 to	 override	
dysregulated	signalling	in	GiPSC-derived	NSCs	which	remained	highly	malignant.	This	is	
consistent	with	the	‘epigenetic	progenitor’	model	of	tumorigenesis,	whereby	epigenetic	
silencing	of	PRC-regulated	genes	 is	an	early	step	 in	 tumour	 formation,	prior	 to	global	
epigenetic	 resetting	 and	 further	mutations	 (Feinberg	 et	 al,	 2006;	 Stricker	 &	 Pollard,	












EZH2	 (Suvà	 et	 al,	 2009)	 and	 BMI1	 (Gargiulo	 et	 al,	 2013),	 and	 the	 Trithorax-related	
histone	 methyltransferase,	 MLL	 (Gallo	 et	 al,	 2012).	 GSCs	 have	 also	 been	 shown	 to	
transition	 between	 epigenetic	 states	 in	 response	 to	 environmental	 pressures;	 in	
response	 to	 RTK	 inhibitors,	 a	 transition	 to	 a	 slow-cycling	 ‘persister’	 state	 through	
upregulation	 of	 histone	 demethylases	 KDM6A/B	 and	 Notch	 signalling	 facilitates	 GSC	
resistance	(Liau	et	al,	2017).	
In	 summary,	 lineage-specific	 TFs	 are	 key	 therapeutic	 targets	 in	 GBM.	 Our	 advancing	
knowledge	 of	 the	 core	 transcriptional	 and	 epigenetic	 networks	 driving	 GBM	 should	
therefore	bring	new	possibilities	for	treating	this	disease	(Romani	et	al,	2018).	
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(GTAAACA),	 with	 the	 wings	 and	 flanking	 DNA	 sequences	 modulating	 the	 binding	
specificity	and	affinity	(Cirillo	&	Zaret,	2007).	In	addition	to	DNA-binding	functions,	the	
Forkhead	 domain	 also	 contains	 nuclear	 localisation	 sequences,	 primarily	 at	 the	 C-
terminal	(Romanelli	et	al,	2003),	indicating	a	common	nuclear	import	mechanism.			
1.4.2 Varied expression patterns, domain structures, protein partners and 
PTMs confer Forkhead factors with a diverse range of functions  
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Distinct	post-translational	modifications	 (PTMs)	and	protein	 interactions	 introduce	 a	
further	layer	of	functional	diversity	between	the	Fox	factors.	While	Forkhead	factors	are	
thought	 to	mostly	 bind	DNA	as	monomers,	 evidence	 exists	 for	 some	 binding	 in	 both	
homodimeric	and	heterodimeric	forms.	For	example,	the	crystal	structures	of	FOXP2	and	





Fox	protein	binding	partners	are	not,	however,	 limited	 to	other	 family	members.	Fox	
factors	 can	 also	 interact	 with	 other	 transcriptional	 regulators,	 such	 as	 Smad	 and	
homeodomain	 factors	(Blount	et	al,	2009;	Wijchers	et	al,	2006).	Forkhead	 factors	are	
also	known	to	interact	with	various	protein	cofactors,	both	activators	and	repressors,	to	
regulate	 transcription;	 for	 example,	 FoxM1	 and	 FoxA	 factors	 can	 recruit	 DNA	
methyltransferases	 and	HDACs	 to	 facilitate	 chromatin	 compaction	 (Lam	 et	 al,	 2013).	
Furthermore,	members	of	the	FoxK	subfamily	contain	a	 ‘Forkhead-associated	domain’	
which	recognises	and	binds	to	phosphorylated	threonine	residues	to	mediate	protein-
protein	 interactions,	 and	 FoxO	 family	 members	 have	 been	 shown	 to	 associate	 with	
multiple	 nuclear	 receptors	 (Wijchers	 et	 al,	 2006).	 A	 recent	 tandem-affinity	
purification/mass	 spectrometry	 study	 analysed	 the	 interactome	 of	 37	 Fox	 factors	 in	
human	embryonic	 kidney	 cells	 to	 reveal	 that	 each	Fox	 factor	 interacts	with	 a	unique	







Finally,	 PTMs	 are	 known	 to	 modulate	 the	 activity,	 subcellular	 localisation,	 stability,	
binding	efficiency	and	specificity	of	Forkhead	factors;	this	leads	to	the	hypothesis	of	a	
PTM	 code	 of	 TFs	 (Benayoun	 et	 al,	 2011;	 Huang	 &	 Tindall,	 2007)	 and	 adds	 another	






















is	 phosphorylation	 (Eijkelenboom	 &	 Burgering,	 2013).	 Activation	 of	 the	 PI3K-AKT	
pathway	in	response	to	growth	factors	such	as	insulin,	leads	to	phosphorylation	of	FoxO	
factors	and	nuclear	export,	inhibiting	their	transcriptional	activity	(Brunet	et	al,	1999).		
Single	 Fox	 factors	 can	 also	 perform	 distinct	 functions	 during	 development	 and	 in	
adulthood,	as	illustrated	by	FoxA2,	which	controls	liver	and	pancreas	development	in	the	
embryo,	 whilst	 in	 adulthood	 it	 modulates	 insulin	 secretion	 in	 the	 pancreas	 and	
gluconeogenesis	and	bile	production	in	the	liver	(Le	Lay	&	Kaestner,	2010).	
1.4.3 Forkhead factors act as ‘multimodal’ regulators of gene expression 
The	 differences	 in	 tissue-specific	 expression,	 protein	 domains,	 protein-protein	
interactions	 and	 PTMs	 discussed	 above	 confer	 the	 Fox	 factors	with	 a	wide	 range	 of	





Forkhead	 factors	 are	 known	 to	 bind	 directly	 to	 DNA	 Forkhead-response	 elements	 in	
promoters,	 leading	 to	 transcriptional	 activation	 by	 recruitment	 of	 epigenetic	 co-
activators	(Lam	et	al,	2013).	Accumulating	evidence	also	suggests	that	Forkhead	factors	
may	possess	pioneer	activity,	a	characteristic	of	many	reprogramming	factors	(Iwafuchi-
Doi	 &	 Zaret,	 2014),	 enabling	 them	 to	 directly	 bind	 and	 alter	 the	 structure	 of	 closed	
chromatin	at	specific	loci	to	facilitate	changes	in	transcription	rate.	The	most	well-known	
example	for	this	function	is	FOXA1	and	FOXA2,	whose	pioneer	activity	is	known	to	be	
required	 for	 oestrogen	 and	 androgen	 receptor	 binding	 to	 DNA	 (Carroll	 et	 al,	 2005;	











co-repressors.	 FoxK1,	 for	 example,	 forms	 a	 co-repressor	 complex	 with	 Sin3b,	 a	
scaffolding	 protein	 that	 is	 part	 of	 a	 complex	 including	 HDACs	 and	 nucleosome	









































mechanisms,	 including	 direct	 displacement	 from	 target	 gene	 promoters.	Note	 that	 this	 figure	
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mutation	or	 aberrant	PTMs	 in	 cancer,	 and	 their	 resulting	abnormal	 functions	driving	
tumorigenesis	(Lam	et	al,	2013;	Myatt	&	Lam,	2007).	In	fitting	with	their	capacity	to	both	
activate	 and	 repress	 transcription,	 compelling	 evidence	 suggests	Fox	 factors,	 such	 as	
FoxM1	and	FoxO3,	can	act	as	either	oncogenes	or	tumour	suppressors	in	cancer	(Lam	&	
Gomes,	2014).	As	such,	these	factors	present	promising	candidate	therapeutic	targets.	
Although	 studies	 are	 being	 carried	 out	 to	 target	 TFs	 therapeutically,	 for	 example	 by	
modulating	 protein	 expression	 or	 degradation	 (Lambert	 et	 al,	 2018a),	 they	 are	
intrinsically	difficult	 to	drug	using	small	molecules	due	 to	 their	 lack	of	small,	defined	
ligand	 binding	 sites	 and	 the	 large	 structural	 changes	 that	 occur	 on	 DNA	 binding.	
Understanding	 co-factor	 recruitment	 and	 the	 interactions	 which	 may	 regulate	
subcellular	 shuttling	 and	 recruitment	 to	 transcription	 start	 sites	 may	 lead	 to	 more	
promising	 avenues	 to	 alter	 TF	 function	 (Yan	 &	 Higgins,	 2013;	 Hagenbuchner	 &	
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1.4.5 FOXG1, a multidomain neurodevelopmental transcription factor 
FOXG1	 is	 a	 predominantly	 brain-specific	 Forkhead	 family	 TF	 with	 important	
neurodevelopmental	 functions	in	cell	fate	specification.	While	three	FOXG1	 sequences	
were	 previously	 reported,	 the	 human	QIN	 gene,	 HFK1	 and	 BF1	 (Murphy	 et	 al,	 1994;	
Kastury	et	al,	1994;	Wiese	et	al,	1995),	these	were	later	found	to	all	map	to	the	same	
position	of	chromosome	14q12.	FOXG1	is	489	amino	acids	in	length,	encoded	by	a	single	
exon	 gene,	 and	 is	 highly	 conserved	 across	 mammals	 (Bredenkamp	 et	 al,	 2007).	 In	
addition	to	the	DNA-binding	Forkhead	domain,	the	FOXG1	protein	has	two	other	mapped	
functional	 domains:	 the	 Groucho/TLE-1-binding	 domain	 and	 the	 JARID1B-binding	
domain	(De	Filippis	et	 al,	 2011).	Tertiary	 structure	 information	obtained	with	Phyre	




and	 threonine	 271	 (Thr279	 in	 humans),	 whereby	 serine	 phosphorylation	 by	 casein	
kinase	I	induces	nuclear	import	and	threonine	phosphorylation	through	FGF	signalling	
causes	 nuclear	 export	 in	 cortical	 progenitors	 (Regad	 et	 al,	 2007);	 these	 changes	 in	
subcellular	 localisation	 have	 functional	 consequences	 in	 controlling	 neuronal	
differentiation.	 In	 post-mitotic	 neurons,	 Akt-mediated	 phosphorylation	 of	 FOXG1	 in	
response	 to	 IGF	 signalling	 controls	 its	 survival-promoting	 activity,	 however	 this	 is	
thought	 to	be	 through	another	mechanism	as	FOXG1	 remains	predominantly	nuclear	
(Dastidar	 et	 al,	 2011).	 A	 fraction	 of	 FOXG1	 has	 also	 been	 shown	 to	 localise	 to	
mitochondria	in	an	energy-dependent	manner	in	primary	neuronal/glial	cell	lines	and	in	
the	mouse	cortex	(Pancrazi	et	al,	2015),	suggesting	a	role	in	modulating	mitochondrial	
and	 metabolic	 functions.	 Thus,	 the	 subcellular	 localisation	 of	 FOXG1	 may	 play	 an	























protein-protein	 interaction	 with	 the	 androgen	 receptor,	 a	 ligand-dependent	
transcriptional	activator	(Obendorf	et	al,	2007).		
While	the	literature	describes	FOXG1	as	having	predominantly	repressive	functions,		a	
dual	 activity	 of	 FOXG1,	 acting	 as	 a	 transcriptional	 activator	 and	 repressor	 in	 a	









1.4.6 Protein-protein interactions of FOXG1 
In	addition	to	binding	to	FoxO-SMAD	complexes,	FOXG1	has	mapped	binding	domains	to	













Together	 FOXG1	 and	 TLE-1	 have	 a	 repressive	 function	 via	 this	 interaction	 which	 is	
antagonised	 by	 binding	 of	 Grg6	 (Marcal	 et	 al,	 2005).	 TLE	 proteins	 can	 act	 as	
transcriptional	co-repressors	in	a	variety	of	pathways	including	Notch,	Wnt	and	TGFb	











di-	 or	 tri-methylation,	 associated	 with	 active	 transcription,	 and	 subsequent	











essential	 for	 embryonic	 development	 and	 known	 to	 localise	 at	 developmental	 target	
genes	 in	 ESCs	 to	 control	 acquisition	 of	 active	 histone	 modifications	 that	 lead	 to	
differentiation-related	gene	expression	(Schmitz	et	al,	2011;	Albert	et	al,	2013;	Dey	et	al,	
2008).	 In	 addition,	 JARID1B	 may	 act	 to	 recruit	 other	 corepressors,	 for	 example	 it	
interacts	directly	with	HDACs	in	breast	cancer	(Barrett	et	al,	2007).	





has	 been	 reported	 to	 potentiate	 transcriptional	 activation	 by	 the	 androgen	 receptor	
(Xiang	et	al,	2007),	act	as	a	co-activator	of	retinoic	acid	signalling	(Zhang	et	al,	2014)	and	
in	adipogenesis	JARID1	family	proteins	act	as	dual	modulators	of	gene	expression	(Brier	
et	 al,	 2017).	 In	Drosophila,	 the	 Jarid1b	 ortholog,	 Lid,	 acts	 as	 a	 co-activator	 of	 c-Myc	










modifications	 by	 effector	 proteins,	 rather	 than	 the	 modification	 itself,	 determine	
biological	 outcome	 (Fischer	 et	 al,	 2008;	 Vakoc	 et	 al,	 2005).	 Thus,	 JARID1B,	 although	
established	as	 a	 regulator	 of	 promoter-associated	H3K4	 demethylation,	may	 possess	
context-dependent	functions.	
In	conclusion,	while	the	exact	mechanism	of	action	of	FOXG1	remains	unclear,	it	is	clearly	













indicate	 phosphorylation	 of	 serine	 or	 threonine	 residues	 known	 to	 control	 subcellular	
localisation	 (Regad	 et	 al,	 2007).	Figure	adapted	 from	 (De	Filippis	et	 al,	 2011).	 (B)	 Schematic	
describing	reported	DNA	binding-dependent	and	-independent	functions	of	FOXG1.	FoxO	factors	
act	 as	 signal	 integrators	 to	 control	 cell	 proliferation	 through	 transcription	 of	 p21Cip1.	 IGF-1	
signalling	results	in	Akt-mediated	phosphorylation	of	FoxO	factors	and	nuclear	export,	whereas	
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1.4.7 FOXG1 in brain development and neurodevelopmental disorders 
FOXG1	plays	vital	roles	during	brain	development.	It	is	one	of	the	earliest	TFs	expressed	
in	 the	 anterior	 neural	 plate	 that	 gives	 rise	 to	 the	 telencephalon.	 The	 telencephalon	
includes	progenitors	that	give	rise	to	the	neocortex	in	mammals	(Manuel	et	al,	2010).	
Deletion	 of	 Foxg1	 in	 mice	 is	 lethal,	 resulting	 in	 premature	 differentiation	 of	 neural	
progenitors	in	the	telencephalon,	and	hence	an	excess	in	early-born	neuron	production	
(Xuan	et	al,	1995;	Hanashima	et	al,	2004).	In	contrast,	overexpression	of	FoxG1	results	
in	 increased	 proliferation	 of	 neural	 progenitors	 and	 reduced	 differentiation	
(Bourguignon	et	al,	1998).	This	control	over	telencephalic	proliferation	was	shown	to	be	
cell	 autonomous,	 with	 an	 underrepresentation	 of	 Foxg1	 null	 cells	 found	 in	 chimeric	
mouse	 embryos	 (Manuel	 et	 al,	 2011)	 and	 likely	 to	 be	 mediated	 through	 FOXG1’s	
transcriptional	 repression	 of	 cyclin-dependent	 kinase	 inhibitors	 (p27XIC1	 in	 Xenopus,	
homologous	to	mammalian	p21CIP1	and	p27KIP1)	(Hardcastle	&	Papalopulu,	2000).	
In	 cortical	 progenitor	 cells,	 FOXG1	 opposes	 the	 anti-proliferative	 and	 differentiating	
effects	 of	 TGFb	 signaling	 through	 sequestering	 FoxO-SMAD	 complexes	 and	 thereby	




ventral	 patterning	 of	 the	 forebrain,	 accompanied	 by	 complete	 loss	 of	 ventral	
telencephalic	cell	fate	markers	(Martynoga	et	al,	2005);	this	was	associated	with	loss	of	
Shh	 in	 the	 ventral	 telencephalon	 and	 increased	 BMP4	 expression	 in	 the	 dorsal	
neuroepithelium	(Dou	et	al,	1999).	FOXG1	was	later	confirmed	as	a	central	integrator	of	
both	 Shh	 and	 Wnt	 signalling	 to	 control	 telencephalon	 regionalisation	 in	 zebrafish	
development	 (Danesin	 et	 al,	 2009)	 and	 is	 shown	 to	 coordinate	 the	 production	 of	
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suppressing	 and	 activating	 neurogenesis/proliferation	 in	 a	 dose-dependent	 manner	
(Bourguignon	 et	 al,	 1998).	Moreover,	 siRNA	 knock-down	 of	Foxg1,	 in	 comparison	 to	
knockout,	is	able	to	reset	the	timing	of	neurogenesis	rather	than	simply	enhance	neuron	
generation	(Shen	et	al,	2006).		TLE-1,	an	interactor	of	FOXG1,		also	has	known	roles	in	












The	role	of	FOXG1’s	other	previously	reported	protein	partner,	 JARID1B,	 in	 forebrain	
development	 is	 less	 clear.	 JARID1B,	 is	 required	 to	 epigenetically	 repress	 two	master	





proliferation	 and	 neurosphere	 formation	 in	 culture,	 suggesting	 JARID1B	 negatively	
regulates	neurogenesis	(Zhou	et	al,	2016).	However,	it	was	also	shown	to	be	required	for	
the	neural	differentiation	of	ESCs,	but	dispensable	for	differentiation	of	established	NSCs	
(Schmitz	et	 al,	 2011),	 suggesting	 its	 critical	 effects	 are	 at	 an	 earlier	 stage	of	 cell	 fate	
specification.	
The	 importance	of	FOXG1	 in	development	and	adulthood	 is	 further	highlighted	by	its	
involvement	 in	 a	 number	 of	 neurodevelopmental	 disorders.	 Focal	 malformations	 of	
cortical	development	leading	to	paediatric	epilepsy	are	thought	to	be	driven	by	an	AKT-
FOXG1-reelin	 signalling	pathway	 (Baek	et	 al,	 2015).	Haplosufficiency	of	novel	FOXG1	


















shown	to	 lead	 to	abnormal	 localisation	of	FOXG1	 in	nuclear	 foci	and	altered	CDKN1A	
expression		(Guen	et	al,	2011).	Furthermore,	mutations	have	been	reported	to	lead	to	
altered	dynamics	of	 chromatin	binding	 (De	Filippis	et	 al,	 2011).	Mitter	et	 al	 recently	
reviewed	 83	 patients	 and	 found	 more	 severe	 phenotypes	 were	 associated	 with	
truncating	mutations	 in	 the	N	terminal	or	Forkhead	domain	(Mitter	et	al,	2018).	This	
provides	further	evidence	of	the	importance	of	FOXG1’s	mapped	domains	to	its	function.	
1.4.8 FOXG1 in cellular reprogramming 
A	role	 for	FOXG1	 in	reprogramming	of	cell	 fate	has	also	been	recently	demonstrated.	
Together	Foxg1,	Sox2	and	Brn2	are	able	to	direct	the	conversion	of	mouse	fibroblasts	or	
mouse	astrocytes	 into	tripotent	neural	precursors	(Lujan	et	al,	2012;	Ma	et	al,	2018).	





1.4.9 FOXG1 in cancer  
As	with	many	developmental	genes,	FOXG1	has	a	role	in	numerous	types	of	cancer,	with	
reports	 suggesting	 actions	 as	 both	 a	 tumour	 suppressor	 and	 an	 oncoprotein.	 For	
example,	 in	 cervical	 cancer	miRNA-mediated	 downregulation	 of	 FOXG1	 is	 associated	
with	 increased	 cell	 proliferation	 and	metastasis	 (Zeng	 et	 al,	 2016).	 In	 breast	 cancer,	
FOXG1	acts	 as	 a	 tumour	 suppressor	by	 compromising	 the	 formation	of	 a	 coactivator	
complex	 at	 the	 promoter	 of	 AIB1,	 a	 frequently	 upregulated	 steroid	 receptor	 that	
potentiates	 activation	 by	 hormonal	 receptors	 (Li	 et	 al,	 2013).	 In	 contrast,	 in	 ovarian	







maintaining	 the	 stem	 cell	 state	 of	 GSCs.	 Data	 from	 the	 TCGA	 (Brennan	 et	 al,	 2013),	
accessed	 via	 the	 cBioPortal	 for	 Cancer	 Genomics	 (developed	 at	 the	 Memorial	 Sloan	
Kettering	Cancer	Centre)	 reveal	 FOXG1	 is	 only	mutated	 in	4	out	 of	 291	patient	GBM	
samples,	with	 no	 amplifications.	 However,	 comparison	 of	 the	 transcriptional	 state	 of	
genetically-normal	NS	cells	and	GNS	cells	identified	FOXG1	to	be	the	most	consistently	
overexpressed	gene	in	GBM	across	tumour	subtypes	(Engström	et	al,	2012),	a	finding	
later	 confirmed	 at	 the	 protein	 level	 (Bulstrode	 et	 al,	 2017).	 High	 FOXG1	 levels	 are	
associated	 with	 adverse	 treatment	 outcomes	 and	 a	 decrease	 in	 overall	 survival	
(Robertson	et	al,	2015;	Wang	et	al,	2018;	Verginelli	et	al,	2013).	While	the	reason	for	








lineage-specific	 TFs	FOXG1	 and	 SOX2	 are	 able	 to	 drive	 the	 reactivation	 of	 astrocytic	
dormant	quiescent	NSCs	to	a	proliferative	radial	glia-like	state	(as	further	described	in	
the	 introduction	 of	 Chapter	3).	 CRISPR/Cas9-mediated	 ablation	 of	FOXG1	 in	primary	
human	 GNS	 cells,	 in	 which	 FOXG1	 levels	 are	 elevated,	 resulted	 in	 a	 failure	 to	 form	





expressed	 higher	 levels	 of	 the	 astrocyte	 markers,	 GFAP	 and	 S100b,	 than	 wild-type	





effects	 were	 phenocopied	 by	 knockdown	 of	 TLE-1	 or	 inhibition	 of	 the	 FOXG1:TLE-1	































U87MG	 cells,	 via	 inhibition	 of	 TGFb	 signalling,	 was	 first	 suggested	 by	 Seoane	 et	 al.	
(Seoane	 et	 al,	 2004).	 Similarly,	 in	 medulloblastoma,	 the	 most	 common	 paediatric	
primary	brain	tumour,	a	decrease	in	FOXG1	levels	is	associated	with	increased	survival	
in	mice	(Adesina	et	al,	2015)	and	high	FOXG1	in	tumours	is	reported	to	disrupt	TGFb	
signalling	 that	 normally	 controls	 neuronal	 differentiation	 (Adesina	 et	 al,	 2007).	
However,	more	recent	studies	have	shown	that	TGFb	signalling	can	have	paradoxically	
oncogenic	actions.	The	TGFb	ligand	is	often	upregulated	in	malignant	gliomas	in	which	
cells	 can	 selectively	 disable	 the	 tumour	 suppressor	 arm	 of	 TGFβ	 signalling,	 through	
either	 loss	of	p15INK4b,	 inactivation	of	RB	or	PI3K	hyperactivation.	TGFβ	can	therefore	
stimulate	the	production	of	mitogens,	such	as	platelet-derived	growth	factor	β	(PDGF-β),	
to	 drive	 glioma	 cell	 proliferation	 (Massagué,	 2008;	 Peñuelas	 et	 al,	 2009).	 There	 is	
therefore	contrasting	evidence	for	the	connection	of	FOXG1	and	TGFb		in	GBM;	FOXG1	
may	act	to	repress	functional	TGFb	signalling,	or	where	the	tumour	suppressive	arm	is	






Thus,	 the	 functions	 of	 FOXG1	 in	 development	 can	 provide	 clues	 as	 to	 how	 its	
dysregulated	 signalling	 acts	 in	 GBM;	 however,	 the	 key	 signalling	 pathways	 and	
downstream	effectors	through	which	it	drives	GSCs	remain	unclear.	
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1.5 In vitro models of glioblastoma 





1.5.1 Neural stem cells in mammalian brain development and adulthood 
Given	GBM	is	a	disease	of	NSC-like	cells,	with	a	hierarchy	recapitulating	that	of	neural	
development,	 it	follows	that	 in	vitro	cultures	of	NSCs	provide	an	invaluable	system	to	




tissue	(Pollard	&	Conti,	 2007).	Distinct	 types	of	 primary	neural	progenitor	 cells	 have	
been	identified	in	vivo	at	various	developmental	stages;	these	produce	specific	types	of	
neurons	 and	 glial	 cells,	 often	 through	 several	 divisions	 of	 fate-restricted	 progenitors	
(Kriegstein	&	 Alvarez-Buylla,	 2009).	 These	 regionally	 and	 temporally	 distinct	 neural	
stem/progenitor	cells	all	share	the	 	same		neuroepithelial-radial	glia-astrocyte	lineage	
(Alvarez-buylla	et	al,	2001).		
During	embryonic	development,	 the	earliest	and	most	primitive	 form	of	NSCs	are	 the	
neuroepithelium;	these	make	up	the	neural	plate	in	gastrulated	embryos	(embryonic	day	
7.5	(E7.5)	in	mice)	which	then	forms	the	neural	tube	(E8.5)	(Götz	&	Huttner,	2005).	At	
the	 time	 of	 cortical	 neurogenesis	 (E9.5),	 neuroepithelium	 in	 the	 neural	 tube	 acquire	
features	of	glial	cells	and	become	radial	glia	(RG)	or	apical	progenitors;	these	RG	cells	




pool	 and	 generate	 intermediate	 or	 transit-amplifying	 progenitor	 cells,	 which	 then	
generate	glial	and	neuronal	cell	lineages.	RG	cells	maintain	contact	with	the	ventricles	
throughout	cortical	development,	following	which	they	migrate	to	the	cortical	plate	and	
transform	 into	 astrocytes.	 Inherently,	 much	 of	 our	 knowledge	 of	 mammalian	 brain	
development	comes	from	studies	in	rodents;	while	many	of	these	findings	are	applicable	
to	 humans,	 differences	 are	 expected	 due	 to	 variations	 in	 brain	 complexity.	 New	
populations	of	neural	progenitors	continue	to	be	identified;	for	example,	a	population	of	
outer	RG	cells	in	the	expanded	outer	SVZ	of	humans	are	 thought	 to	 lead	to	 increased	
cortical	complexity	and	size	(Hansen	et	al,	2010;	Johnson	et	al,	2015).	
In	adulthood,	NSCs	persist		in	restricted	areas	of	the	brain	as	type	B	astrocytes	in	the	SVZ	
and	 radial	 astrocytes	 in	 the	 SGZ	 (Braun	&	 Jessberger,	 2014)	 (section	1.1.3).	While	 a	
subset	 of	 RG	 cells	 remain	 neurogenic	 after	 birth	 in	 some	 species,	 such	 as	 songbirds,	
lizards	and	fish	(Merkle	&	Alvarez-buylla,	2006),	in	mammals	they	disappear	following	
birth,	 after	 giving	 rise	 to	 neural	 and	 glial	 progenitor	 cells	 and	 adult	 SVZ	 stem	 cells	
(Merkle	et	al,	2004).	Type	B	cells	retain	epithelial	properties	by	possessing	apical	and	














Illustration	 depicting	 the	 continuous	 lineage	 of	 NS	 cells	 present	 in	 the	 developing	 and	 adult	







of	 embryonic	 development,	 most	 RG	 cells	 migrate	 through	 the	 cortical	 plate	 and	 become	
astrocytes,	possibly	through	an	intermediate	progenitor	cell	stage.	A	subset	of	RGs	in	the	neonate	
continue	to	produce	neurons	and	oligodendrocytes,	as	well	as	ependymal	cells	and	type	B	cells.	
These	 type	 B	 cells	 function	 as	 SVZ	 NS	 cells	 into	 adulthood,	 maintaining	 contact	 with	 the	
vasculature	and	ventricle	surface	through	their	apico-basal	polarity.	They	continue	to	produce	
glial	and	neural	cells	 in	the	adult	brain.	Solid	arrows	are	supported	by	experimental	evidence;	
dashed	 arrows	 are	 hypothetical.	 MA,	 mantle;	 MZ,	 marginal	 zone;	 NE,	 neuroepithelium;	 SVZ,	
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1.5.2 In vitro culture of tissue-derived neural stem cells  
The	first	in	vitro	culture	of	multipotent	and	clonogenic	NSCs	was	reported	in	1989	from	




Cattaneo,	 2010).	 Expansion	 of	 multipotent	 neural	 progenitor	 cells	 from	 the	 adult	
mammalian	brain	(mouse	foetal	CNS)	(Reynolds	&	Weiss,	1992)	was	first	achieved	as	
non-adherent	 free-floating	 aggregates,	 or	 neurospheres,	 using	 serum-free	 medium	
supplemented	 with	 epidermal	 growth	 factor	 (EGF).	 However,	 the	 spontaneous	
organisation	 of	 neurosphere	 cultures	 leads	 to	 heterogeneity	 and	 issues	 with	
reproducibility	(Pollard	&	Conti,	2007;	Pastrana	et	al,	2011).	3D	organoid	cultures	that	
maintain	 tissue	 architecture	 have	 since	 been	 developed	 and	 are	 beneficial	 where	
experiments	 require	 accurate	 recapitulation	 of	 the	 in	 vivo	 niche	 structure.	 However,	






















molecular	 apparatus	 of	 radial	 glia-like	 neural	 progenitors,	 namely	 self-renewal	 and	
differentiation	potential,	and	can	be	termed	RG-like	NS	cells.		
1.5.3 Differentiation of neural stem cells in vitro  
Adherent	in	vitro	NS	cell	cultures	provide	a	useful	experimental	system	to	explore	the	









In	 addition	 to	 promoting	 astrocytic	 maturation,	 SMAD	 signalling	 inhibits	
oligodendroglial	 lineage	 commitment	 through	 upregulation	 of	 Id2/4	 proteins,	 which	
subsequently	indirectly	or	directly	sequester	OLIG	and	E2A	factors	(Samanta	&	Kessler,	
2004).	Glial	fibrillary	acidic	protein	(Gfap)	was	the	first,	and	is	still	the	most	widely	used,	




NSCs,	 Gfap-negative	 protoplasmic	 astrocytes	 and	 increasing	 knowledge	 of	
astrogliogenesis	led	 to	 the	 identification	of	other	markers,	 including	S100b	and	Aqp4	
(Molofsky	et	 al,	 2012;	Bignami	et	 al,	 1972;	Walz	&	Lang,	1998;	Nielsen	et	 al,	 1997)	 .	
Currently	we	therefore	rely	on	using	a	combination	of	astrocytic	markers	to	denote	a	
mature	 astrocytic	 state.	 Furthermore,	 quiescent	 NSCs,	 reminiscent	 of	 type	 B	 SVZ	
astrocytes,	have	been	shown	to	be	driven	by	 the	 interaction	between	BMP4	and	FGF	
signalling	 (Martynoga	 et	 al,	 2013;	 Sun	 et	 al,	 2011).	 These	 cells	 upregulate	 astrocyte	
markers	however	retain	 the	ability	 to	re-enter	cell	 cycle	upon	re-exposure	 to	growth	
factors.	This	state	was	also	shown	to	be	achieved	in	our	lab	using	BMP4	at	high	plating	
densities	 (Bulstrode,	 2015).	 Although	 being	 actively	 explored,	 definitive	 markers	 of	
these	 quiescent	 cells	 are	 currently	 lacking;	 therefore,	 they	 can	 be	 functionally	
distinguished	from	mature	astrocytes	by	their	ability	to	re-establish	proliferation.		
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1.5.4 Human patient-derived GNS cells 
Efforts	 to	 isolate	 and	expand	 the	GBM	stem	cell	 fraction	driving	brain	 tumours	were	
initially	 achieved	 using	 neurosphere/suspension	 culture	 conditions	 developed	 for	
normal	NSCs	(serum-free	media	with	EGF	and	FGF-2)	(Galli	et	al,	2004;	Singh	et	al,	2003).	
These	 cultures	 provide	 more	 disease-relevant	 models	 than	 previously	 established		
serum-cultured	 glioma	 cell	 lines	 and	 were	 shown	 to	 recapitulate	 parental	 tumour	





stem	 (GNS)	 cells.	 Unlike	 suspension	 cultures,	 these	 culture	 conditions	 enabled	
derivation	 of	 GNS	 cell	 lines	 from	 all	 tumour	 samples	 tested,	 that	 retained	 their	
tumorigenic	 potential	 following	 long-term	 expansion.	While	 3D	 ‘tumourspheres’	 can	
better	recapitulate	features	such	as	tumour	hypoxia	and	invasion,	2D	adherent	models	
provide	a	uniform	culture	required	to	assess	the	behaviour	and	biochemistry	of	GSCs	






with	 the	 CRUK	 University	 College	 London	 centre.	 This	 resource	 is	 generating	 a	
comprehensive	collection	of	patient-derived	GNS	cell	lines,	alongside	control	human	NS	
cell	 lines,	each	matched	with	tumour	tissue	samples	that	will	be	open	to	the	research	












1.5.5 Genome engineering of mouse and human NS cells 
In	recent	years,	CRISPR/Cas9	 technology	has	revolutionised	our	ability	 to	genetically	
modify	 the	genome	of	mammalian	cells,	 in	a	much	quicker	and	more	reliable	manner	






to	 be	 investigated	 (Bressan	 et	 al,	 2017).	 Normal	mouse	NSCs	 often	 provide	 a	 useful	
experimental	 system	 prior	 to	 pre-clinical	 validation	 in	 human	 cultures,	 due	 to	 their	
shorter	doubling	time	and	high	conservation	of	many	GBM-associated	genes	such	as	FOX	
factors.	 Novel	 GBM	mouse	model	 cell	 lines	 can	 now	 be	 produced	with	 relative	 ease,	
especially	when	compared	to	the	time-consuming	and	costly	process	of	mouse	breeding.	
For	example,	mouse	NSCs	can	be	transformed	into	GBM-initiating	cell	lines,	with	deletion	
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or	 overexpression	 of	 various	 tumour	 suppressors	 or	 oncogenes,	 using	 CRISPR/Cas9	
technology	 and	 PiggyBac-mediated	 overexpression,	 respectively	 (E.	 Gangoso,	
manuscript	in	preparation).	This	allows	the	step-wise	addition	of	driver	mutations	and	
analysis	of	 the	effects	on	downstream	signalling	pathways,	 in	comparison	 to	 isogenic	
controls.	The	resulting	cell	lines	also	provide	a	tractable	model	to	study	the	biology	of	
GSCs	due	to	their	faster	growth	rate	compared	to	patient-derived	GNS	cells.	In	addition	









editing	 in	 this	 thesis,	 the	 repurposing	 of	 Cas9	 enzymes	 has	 extended	 CRISPR/Cas9	
technologies	 to	 areas	 of	 gene	 regulation,	 epigenomic	 engineering	 and	 chromatin	
topology	 manipulation,	 highlighting	 the	 versatility	 of	 this	 technology	 and	 its	
transformative	role	in	understanding	gene	function	(Adli,	2018).	In	Chapters	4	and	5	we	
highlight	 the	 use	 of	 CRISPR/Cas9	 technology	 to	 aid	 our	 investigations	 into	 FOXG1’s	
mechanism	in	GSCs.		
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CHAPTER 2 Materials and Methods 
2.1 Cell culture 
2.1.1 Cell line maintenance 
All	cells,	mouse	and	human,	were	cultured	in	an	adherent	monolayer	on	uncoated	tissue	
culture	plastics	and	 incubated	 at	37°C	with	5%	CO2.	Media	was	 exchanged	every	3-4	
days.	 Cells	 were	 dissociated	 once	 70-80%	 confluency	 was	 reached	 using	 Accutase	
solution	(Sigma).	The	frequency	of	passaging	varied	between	cell	 lines.	Mouse	NS	cell	
lines	 were	 passaged	 approximately	 1:6	 every	 3-4	 days.	 Human	 GNS	 cell	 lines	 were	
passaged	 approximately	 1:4	 every	 5-7	 days.	 Cells	 were	 grown	 under	 serum-free	
conditions	in	‘complete’	NS	cell	media.	This	media	consists	of	DMEM/HAMS-F12	(Sigma	
D8437)	 supplemented	 with	 N2	 and	 B27	 (Life	 Technologies/Gibco),	 penicillin-
streptomycin	(Gibco),	BSA	(Gibco),	b-mercaptoethanol	 (Gibco),	MEM	NEAA	(Gibco),	1	
μg/ml	Laminin	(Sigma	or	Cultrex),	10	ng/ml	mouse	EGF	and	10	ng/ml	human	FGF-2	
(Peprotech).	 During	 passaging,	 cells	 were	 collected	 in	 wash	 media,	 consisting	 of	
DMEM/HAMS-F12	supplemented	with	Pen-Strep	and	BSA	only.	For	cryo-preservation,	
cells	were	 frozen	at	 -80°C	 following	resuspension	of	a	cell	pellet	of	approximately	½	





















10	 cells/mm2	 in	NS	 cell	media	 in	 the	 absence	 of	 EGF/FGF-2	 and	 supplemented	with	
BMP4	(10	ng/ml,	Peprotech).	Cells	were	treated	for	1	day	or	3	days	as	indicated.	
2.2 Design of reagents for genetically engineering cell lines 




2.2.2 Guide RNA design for CRISPR/Cas9-mediated gene knock-out 
CRISPR	guide	RNAs	(gRNAs)	were	designed	using	the	Optimised	MIT	CRISPR	Design	tool	
(http://crispr.mit.edu).	 gRNAs	 were	 selected	 based	 on	 their	 specificity	 to	 unique	
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coding	 exon,	 by	 Dr	 Raul	 Bressan	 and	 Dr	 Maria	 Kalantsaki,	 respectively.	 Plasmid	
construction	(sp322	and	sp199)	was	previously	performed	by	Dr	Raul	Bressan	and	Dr	





Genetic	disruption	of	FOXG1	 from	 the	human	GNS	 cell	 line	G313	was	achieved	using	
delivery	of	a	pre-assembled	Cas9	ribonucleoprotein	(RNP)	complex,	made	up	of	Cas9,	




with	 the	 tracrRNA.	 The	 67-nt	 tracrRNA	 contains	 the	 gRNA-scaffold	 region	 and	16-nt	
sequence	 complementary	 to	 the	 crRNA.	 The	 backbone	 and	 ends	 of	 both	 synthetic	
RNAs	 had	 been	 chemically	 modified	 by	 IDT	 to	 make	 them	 resistant	 to	 nuclease	
digestion,	limit	cellular	immune	responses	and	increase	stability	(Rahdar	et	al,	2015;	
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Kelley	 et	 al,	 2016).	 	 Lyophilised	 crRNA	 and	 tracrRNA	 pellets	 were	 resuspended	 in	
Duplex	 buffer	 (IDT)	 to	 achieve	 a	 100µM	 (100	 pmol/µl)	 concentration	 and	 stored	 in	
aliquots	at	-80°C.	Recombinant	Cas9	protein	was	produced	in-house	by	Dr	Carla	Blin	
(Pollard	lab),	as	described	in	(Dewari	et	al,	2018).	
2.2.3 Guide RNA and donor DNA design for CRISPR/Cas9-mediated gene 
tagging 
For	 epitope-tagging	 of	 endogenous	 genes	 (FoxO6,	 Foxg1	 and	 FOXG1),	 gRNAs	 were	
designed	to	target	the	3’	end	of	the	last	coding	exon	(the	second	exon	of	FoxO6	and	only	
coding	exon	of	Foxg1/FOXG1).	gRNAs	were	chosen	to	cut	10-20	bp	downstream	of	the	
stop	 codon	 in	 the	 3’	 UTR	 to	 avoid	 disruption	 of	 the	 coding	 sequence.	 crRNAs	 and	
tracrRNAs	were	prepared	and	stored	as	above.	For	HA-tagging	of	FoxO6	and	V5-tagging	












Gene	 Synthesis	 (Thermo	Scientific),	 and	 supplied	 following	 sequence	 verification	
and	cloning	into	a	pMX	series	vector	with	kanamycin	resistance.	PCR	amplification	and	
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product	 purification	 was	 performed	 to	 obtain	 a	 high	 concentration	 of	 linear	 dsDNA	
donor	 template	 (primers	 in	 Appendix	 VI).	 SYBR	 Safe	 was	 used	 to	 visualise	 the	 PCR	
product.	PCR	product	purification	was	performed	using	NucleoSpinTM	Gel	and	PCR	Clean-
up	 Kit	 (Macherey-NagelTM),	 and	 eluted	 in	 20-30	 µl	 of	 elution	 buffer	 to	 achieve	 a	
concentration	 of	 approximately	 200	 ng/µl.	 Prior	 to	 transfection,	 formation	 of	 linear	
single-stranded	DNA	was	promoted	by	incubating	300	ng	of	dsDNA	donor	template	at	
95°C	for	5	min	in	33%	DMSO,	followed	by	immediate	cooling	on	ice.	
2.3 Derivation of genetically engineered cell lines 







Tet-On	 3G	 transactivator	 protein,	 rtTA)	 and	 the	 TetOn	 FOXG1_V5	 expression	 vector	
(sp171)	in	a	2:1:1	ratio.	Following	recovery,	cells	were	transferred	from	a	6	well	plate	to	
a	T25	flask.	Dox	was	added	to	the	media	(1000	ng/ml)	for	24	h.	Selection	for	integration	





Chapter 2 | Materials and Methods 
 
 68 
stable	 transgene	 expression	 between	 independent	 experiments.	 The	 resulting	
populations	were	 expanded	 for	3-4	days	 in	NS	 cell	media	 prior	 to	 functional	 assays,	
during	which	time	existing	FOXG1-V5	protein	was	degraded.	
2.3.2 CRISPR/Cas9-mediated gene knockout 







the	 transfection	 efficiency	 estimated	 in	 the	 bulk	 sorted	 population	 by	
immunocytochemistry	(ICC).	For	derivation	of	clonal	cell	lines,	300	cells	were	plated	per	
10	cm	dish.	After	10-15	days,	discrete	colonies	were	picked,	expanded,	and	screened	for	
successful	 disruption	 of	 Foxg1	 by	 PCR	 genotyping	 and	 ICC.	 Loss	 of	 FOXG1	 protein	
expression	was	further	validated	by	Western	blotting.		
For	deletion	of	FOXG1	in	the	human	GNS	cell	line	G313,	cells	were	transfected	using	the	










transfection	 buffer.	 Transfection	 was	 performed	 by	 a	 Masters	 student,	 Shruthi	
VijayKumar.	 Following	 recovery,	 loss	 of	 FOXG1	 protein	 was	 assessed	 by	 ICC.	 For	












by	 PCR	 genotyping	 and	 ICC.	 For	 3xFLAG-HA-p2A-eGFP	 tagging	 of	 FOXG1,	 300	 ng	
denatured	dsDNA	was	included	per	transfection	and	the	Amaxa	4D	programme	DN100	
used.	Transfected	 cells	were	 expanded	 into	T150	 flasks	and	eGFP	positive	 cells	were	
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2.4 DNA-based analyses 
2.4.1 PCR-based genotyping of genetically engineered cell lines 
Genomic	 DNA	 (gDNA)	 isolation	 from	 bulk	 transfected	 cells	 and	 clonal	 cell	 lines	was	
performed	 using	 the	 DNeasy	 Blood	 and	 Tissue	 kit	 (Qiagen),	 according	 to	 the	
manufacturer’s	 protocol.	 DNA	 concentrations	 were	 quantified	 using	 a	 NanoDropTM	
spectrophotometer.	 All	 primers	 were	 designed	 using	 Primer3	 software	
(http://primer3.ut.ee)	 and	 are	 listed	 in	 Appendix	 VI.	 To	 identify	 NHEJ-based	 indel	
formation,	 the	region	 flanking	 the	gRNA	target	site	was	amplified	using	gene-specific	
primers.	In	the	case	of	Foxg1	deletion	from	IENS-GFP,	primers	were	designed	flanking	






difficult.	 PCR	genotyping	was	 therefore	performed	with	one	primer	outside	of	 the	3’	
homology	arm	in	a	gene-specific	region,	and	the	other	within	the	eGFP	sequence.	PCR	
products	were	analysed	using	1-2.5%	agarose	gels	with	EtBr	and	GeneRulerTM	1kB	plus	
DNA	 ladder	 (Thermo	 Scientific).	 Gels	 were	 imaged	 on	 a	 UV	 gel	 reader	 or	 Bio-Rad	
ChemiDocTM	Imager.		
 
2.4.2 Reduced-representation bisulfite sequencing (RRBS) 
RRBS	was	performed	as	described	in	(Bulstrode	et	al,	2017).		Library	preparation	and	
sequencing	were	performed	at	 the	Edinburgh	Clinical	Research	Facility.	Analysis	was	




Dox-inducible	 FOXG1-V5	 expression)	 using	 the	 MasterPureTM	 Complete	 DNA	
purification	kit	(Epicentre)	from	three	independent	experiments	and	concentrated	with	
the	DNA	Clean	and	Concentrator	kit	(Zymo	Research)	before	being	quantified	using	a	
Qubitâ	 dsDNA	 broad-range	 assay	 kit	 (Thermo	 Scientific)	 and	 NanoDropTM	
spectrophotometer.	 85	 ng	 of	 each	 purified	 gDNA	 sample	 was	 processed	 using	 the	
Ovation	RRBS	Methyl-Seq	system	kit	(NuGEN	Technologies).	Unmethylated	phage	λ	DNA	
(0.5	 ng)	 was	 spiked	 into	 each	 sample	 to	 allow	 assessment	 of	 bisulfite	 conversion	
efficiency.	 Briefly,	 the	 methylation-insensitive	 restriction	 enzyme	 MspI	 was	 used	 to	
digest	 the	 gDNA,	 and	 digested	 fragments	 were	 ligated	 to	 adapters.	 Adapter-ligated	
fragments	were	then	repaired	before	bisulfite	conversion	with	the	EZ	DNA	Methylation-
Lightning	 kit	 (Zymo	 Research).	 Bisulfite-treated	 adapter-ligated	 fragments	 were	
amplified	 by	 15	 cycles	 of	 PCR	 and	 purified	 using	 Agencourt	 RNA	 Clean	 XP	 beads.	
Libraries	 were	 quantified	 using	 the	 Qubit	 dsDNA	 high-sensitivity	 assay	 (Thermo	
Scientific)	 and	assessed	 for	 size	 and	quality	using	 the	Agilent	Bioanalyzer	DNA	high-
sensitivity	 kit.	 Sequencing	 was	 performed	 using	 the	 NextSeq	 500/550	 high-output	
version	 2	 kit	 (150	 cycles;	 Illumina)	 on	 the	 NextSeq	 550	 platform.	 Libraries	 were	
combined	into	equimolar	pools	and	run	across	four	flow	cells.		
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with	0.1%	Triton)	 for	20	min	 for	 permeabilisation.	 Cells	were	 incubated	 in	 blocking	
solution	(PBST	with	0.1%	BSA	and	3%	goat	serum)	for	1	hr,	before	overnight	incubation	
at	4°C,	with	primary	antibody	in	blocking	solution.	Primary	antibody	was	removed	with	




performed	 using	 a	 Nikon	 TiE	 microscope	 and	 NIS-Elements	 software.	 Analysis	 was	
performed	 using	 FIJI	 (Image	 J)	 software.	 Quantification	 of	 immunopositive	 cells	was	
performed	using	 the	Cell	 Counter	plugin.	Total	 cell	 number	was	determined	by	DAPI	
staining.	Quantification	of	Gfap	and	Nestin	staining	in	Chapter	3	and	FOXG1-V5	staining	
in	Chapter	4	was	performed	using	PerkinElmer’s	Operetta	High-content	imaging	system	
and	 Columbus	 software.	 A	 list	 of	 antibodies	 used	 for	 ICC	 and	Western	 blotting	 are	
provided	in	Appendix	V.	
2.5.2 Western blotting 
Cell	pellets	were	resuspended	in	70	ul	of	RIPA	buffer	(50	mM	Tris-HCl	pH	8.0,	150	mM	
NaCl,	1%	NP-40,	0.5%	deoxicholate,	0.1%	SDS	and	protease	inhibitors	(Complete,	Roche,	
11697498001)).	 Following	 incubation	 for	 5	 min	 on	 ice,	 the	 resuspension	 was	
centrifuged	at	13000	rpm	for	10	min	at	4	˚C.	The	supernatant	was	collected	in	a	clean	
tube	 and	 quantified	 using	 Thermo	 Scientific	 BCA	 kit	 (cat.	 23227).	 25%	 of	 the	 total	
volume	of	4x	Lithium	dodecyl	sulfate	(LDS)	buffer	containing	10%	2-mercaptoethanol	
was	 added	 and	 samples	 were	 denatured	 at	 95˚C	 for	 10	 min.	 Electrophoresis	 was	
performed	using	Tris-Bis-HCl	buffered	(pH	6.4)	4-12%	polyacrylamide	gels	made	by	Dr	
Carla	 Blin,	 Pollard	 lab.	 Spectra	 Multicolour	 Broad	 Range	 Protein	 Ladder	 (Thermo	
Scientific)	or	BioRad	Precision	Plus	Protein	Dual	Colour	standards	were	used.	Protein	
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PBS-T	 at	 room	 temperature	with	 rocking	 for	 at	 least	30	min.	 For	 each	 antibody	 the	
amounts	added	were:	~	10	µg	of	anti-FOXG1	(17B12	in	glycerol),	10	µg	of	mouse	IgG	


















was	 added	 to	 cells	 at	 a	 1:1000	 dilution	 as	 a	 live/dead	 stain.	 Flow	 cytometry	 was	
performed	 on	 a	 BD	 FACS	 Aria	 II	 or	 BD	 FACS	 Fusion	 cell	 sorter	 by	 the	 SCRM	 Flow	
Cytometry	Core	Facility.	FACSDiva	software	was	used	for	data	collection.		
2.6 RNA-based analyses 
2.6.1 qRT-PCR  
RNA	extraction	was	performed	using	the	MasterpureTM	RNA	purification	kit	according	to	
the	manufacturer’s	instructions	(Epicentre).	DNase	digestion	was	performed	using	RQ1	




was	 determined	 using	 the	 Qubitâ	 RNA	 High	 Sensitivity	 kit	 (Thermo	 Scientific)	 or	
NanoDropTM	Spectrophotometer.	Within	each	experiment,	the	same	amount	of	RNA	was	
inputted	 for	 cDNA	 synthesis.	 Reverse	 transcription	 was	 performed	 using	 Invitrogen	
Superscript	III.	RNA	samples	were	made	up	to	a	volume	of	11	µl	in	RNase-free	water;	to	
each	 sample,	 1µl	 Oligo(dT)18,	 1µl	 dNTP	mix	 and	0.5µl	 random	hexamer	 primers	 (all	
Thermo	 Scientific)	were	 added.	 The	 samples	were	 incubated	 at	 65˚C	 for	 5	min,	 then	
cooled	on	 ice	 for	 at	 least	1	min,	 before	 adding	4µl	 5X	FS	buffer,	 1µl	 0.1M	DTT,	0.5µl	








were	 run	on	 each	plate	 to	 ensure	 the	 absence	of	 contamination.	Technical	 replicates	
were	run	to	ensure	pipetting	accuracy.	Data	were	analysed	using	the	ddCt	method;	this	
method	 assumes	 100%	 PCR	 efficiency	 which	 is	 guaranteed	 with	 TaqMan	 assays.	
Replicate	Ct	values	were	averaged	and	normalised	to	the	housekeeping	gene,	Gapdh	(to	
give	dCt).	These	values	were	then	normalised	to	a	calibrator	sample	(to	give	ddCt).	Data	
are	 presented	 as	 log2(fold	 change)	 or	 -	 ddCt,	 where	 this	 value	 equals	 zero	 for	 the	
calibrator,	as	indicated	in	the	figure	legends.	All	TaqMan	assays	used	in	this	thesis	are	
listed	in	Appendix	VII.	




GNS	 cell	 lines	 were	 generated	 by	 the	 Glioma	 Cellular	 Genetics	 Resource	 (GCGR)	
(www.gcgr.org.uk).	RNA-seq	data	from	glioma	primary	tissue	and	matched	derived	GSC	
lines	was	made	available	through	the	GCGR.	A	list	of	cell	 line	names	along	with	GCGR	
names	 is	 provided	 in	 Appendix	 VIII.	 RNA-seq	 data	 was	 analysed	 by	 Ben	 Southgate	
(Pollard	lab).	RNA-seq	Fastq	files	were	aligned	to	the	hg38	transcriptome	as	defined	by	
the	TxDb.Hsapiens.UCSC.hg38.knownGene	R	package	with	 the	pseudo	aligner	kallisto.	





was	 performed	 with	 reference	 to:	 (Soneson	 et	 al,	 2016;	 Martin,	 2011;	 Benjamini	 &	
Hochberg,	 1995;	 Ewels	 et	 al,	 2016;	 Bray	 et	 al,	 2016;	 Love	 et	 al,	 2014;	 Team	 BC,	
Maintainer	 BP,	 2019).	 Supplementary	 RNA-seq	 figures	 and	 tables	 are	 provided	 in	
Appendix	VIII.	
2.7 Functional cell-based assays 
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2.7.2 EdU cell proliferation assay 
For	analysis	of	proliferation	rates,	cells	were	incubated	in	NS	cell	media	with	EGF/FGF-
2,	supplemented	with	10	µM	EdU	for	24	h.	Cells	were	then	fixed	in	4%	PFA	for	10	min	at	




by	 DAPI	 staining.	 Quantification	 was	 performed	 using	 the	 Image	 thresholding	 and	
Particle	Analysis	functions	on	FIJI	software.		









2.7.4 Colony formation following BMP4 treatment 















2.8 Statistical analyses 
Statistical	 analyses	were	 performed	 in	 GraphPad	 Prism	 7.	 Biological	 replicates	 were	
considered	as	different	passage	numbers	of	 the	 same	 cell	 line	plated	 in	 independent	
experiments.	Mean	and	SEM	or	SD,	and	n	numbers,	are	shown	in	the	figure	legends.	Due	






variation	 between	 biological	 replicates	 (e.g.	 growth	 analysis,	 colony	 assays	 following	
BMP4	 treatment).	Where	 significant,	 p	 values	 are	 indicated	 in	Figures	 as	 asterisks,	 *	
p£0.05,	**	p£0.01,	***	p£0.001,	****	p£0.0001.		
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CHAPTER 3  
FOXG1 enforces an NS cell identity through transcriptional 
control of cell cycle and epigenetic regulators  
3.1 Introduction 
GBMs	 frequently	 overexpress	 FOXG1,	 the	 key	 forebrain	 neurodevelopmental	
transcription	 factor.	The	elevated	 levels	of	FOXG1,	and	other	NS	cell	 lineage-affiliated	
master	regulators,	are	thought	to	regulate	the	NS	cell-like	identity	of	GSCs.	However,	the	
mechanisms	by	which	they	do	this	remain	unclear.		In	this	introduction	I	briefly	describe	
data	 from	the	Pollard	 lab,	generated	by	 former	PhD	student	Dr	Harry	Bulstrode.	The	
results	presented	in	this	chapter	build	upon	his	initial	findings.		
To	 establish	 the	 role	 of	 the	 master	 regulators,	 FOXG1	 and	 SOX2,	 on	 NSC	 fate,	






that	 accompany	 FOXG1/SOX2-induced	 quiescent	 NSC	 reactivation	 were	 assessed	 by	
RNA-seq.	The	intersection	of	these	data	sets	led	to	the	discovery	of	a	set	of	candidate	
transcriptional	 target	 genes	 shared	 between	 FOXG1	 and	 SOX2	 (Figure	 3-1).	 This	 set	
included	 enrichment	 of	 cell	 cycle	 regulators,	 chromatin	 modifiers	 and	 NS	 cell	 gene	
ontology	 (GO)	 categories.	TaqMan	arrays	 (TLDAs)	 for	 candidates	 from	each	 category	
indicated	that	FoxO3,	FoxO6,	Chd3	and	Tet3	were	candidate	targets	of	FOXG1/SOX2.		






(A)	 RNA-seq	 analysis	 at	 timepoints	 during	 FOXG1/SOX2-induced	 reactivation	 of	 dormant	
quiescent	mouse	NSCs	with	astrocytic	features.	NS	cells	were	 treated	with	BMP4	 for	24h	and	
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In	 particular,	 the	 Forkhead	 factor	 and	 tumour	 suppressor,	 FoxO3,	 whose	 locus	 was	
bound	by	both	FOXG1	and	SOX2,	was	functionally	validated	as	a	downstream	repressed	
target.	 Deletion	 of	 the	 FOXG1/SOX2-bound	 cis-regulatory	 region	 of	 FoxO3	 abolished	
FOXG1/SOX2-induced	reactivation.	However,	loss	of	FoxO3	itself	was	found	to	drive	cell	
cycle	re-entry	but	not	reacquisition	of	an	NS	cell-like	state.	The	loss	of	astrocytic	markers	






preliminary	data,	we	 therefore	decided	 to	dissect	 its	 role	when	overexpressed	alone,	
without	combined	SOX2	overexpression.	
In	 this	 chapter,	 we	 therefore	 begin	 exploring	 FOXG1’s	 function	 by	 testing	 whether	
overexpression	 of	 a	 human	 FOXG1	 transgene	 alone	 is	 sufficient	 to	 drive	 dormant	
quiescent	mouse	NSCs	to	a	proliferative	radial-glia-like	NSC	state.	We	assess	the	state	of	
these	reactivated	cells	following	withdrawal	of	transgene	induction.	Based	on	a	set	of	
previously	 identified	 candidate	 targets,	 we	 then	 validate	 which	 of	 these	 targets	 are	
regulated	 by	 increased	FOXG1	 alone	 during	 the	 reactivation	 process.	 Finally,	we	 use	
reduced-representation	bisulphite	sequencing	(RRBS)	 to	determine	changes	 in	global	
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3.2 Overexpression of FOXG1 in dormant quiescent NSCs  
The	 ability	 of	 high	 FOXG1	 levels	 alone	 to	 drive	 a	 proliferative	NS	 cell-like	 state	was	





3.2.1 Mouse NS cells enter a dormant quiescent state with astrocytic 
features after 24 h BMP4 treatment 
Adult	mouse	NS	cells	(ANS4,	FS3)	were	plated	at	low	density	(10	cells/mm2)	and	treated	
with	BMP4	(10	ng/ml)	for	24	h.	Cells	plated	at	the	same	density	in	either	EGF/FGF-2	or	
BMP4	 revealed	 strikingly	distinct	 differences	 in	morphology	 and	marker	 expression.	
BMP4-treated	cells	displayed	stellate,	flattened	morphology	characteristic	of	astrocytes,	
whereas	 untreated	 NS	 cells	 had	 a	 bipolar	 phase-bright	 appearance	 (Figure	 3-2	 A).	
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3.2.2 FOXG1 overexpression results in cell cycle re-entry, re-acquisition of an 













+/-	 Dox.	 This	 confirmed	 cell	 cycle	 re-entry	 and	 colony	 formation	 occurred	 following	
FOXG1	overexpression,	with	minimal	background	colony	formation	observed	in	the	no	
Dox	controls	(Figure	3-5	C-E).	Upon	withdrawal	of	Dox,	the	reactivated	cells	continued	
to	 divide	 and	 could	 be	 serially	 passaged.	 The	 expanded	 reactivated	 cells	 displayed	a	































changes	 in	 cell	morphology	 on	 addition	 of	Dox	 (Scale	 bar:	 100	µm).	 (C)	 Number	 of	 colonies	
formed	after	24	h	BMP	treatment	and	10	days	in	EGF/FGF-2	,	with	or	without	Dox	addition.	Mean	
+/-	 SD,	 n=3	 independent	 experiments.	 Each	 data	 point	 shows	 the	 mean	 of	 one	 experiment,	
performed	in	technical	triplicates.	(D)	Colony	formation	in	F6	cells	after	24	h	BMP	treatment	and	
10	days	in	EGF/FGF-2,	with	or	without	Dox	addition.	6	well	plate	stained	with	methylene	blue	
after	 fixation.	(E)	Representative	phase-contrast	 images	of	 cells	with	or	without	Dox	addition	
after	10	days,	following	fixation	and	methylene	blue	staining	(Scale	bar:	200	µm).	
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3.3 FOXG1 transcriptionally controls cell cycle and epigenetic 
regulators 








assay.	RNA	was	 extracted	during	 a	 time-course	 following	 replacement	of	BMP4	with	
EGF/FGF-2,	with	and	without	Dox	addition;	gene	expression	levels	were	subsequently	
determined	using	TaqMan	qRT-PCR	assays	(Figure	3-7	A).	Assessment	of		human	FOXG1	
mRNA	 levels	 confirmed	 significant	 induction	 of	 transgene	 overexpression	 upon	 Dox	
treatment,	with	a	235-fold	upregulation	in	expression	by	day	1	in	Dox	(compared	to	EGF-
FGF2	control,	where	log2(fold	change)	equals	zero)	(Figure	3-7	B).	We	noted	that	for	the	
NS	 cell	marker,	Nestin,	 and	 the	 astrocyte	marker,	Gfap,	 EGF/FGF-2	 alone	 alters	 their	
expression	early	in	the	time-course,	and	this	was	not	significantly	altered	by	Dox	(Figure	
3-7	C	 and	D).	We	 therefore	 focussed	on	 changes	 in	 target	gene	 expression	 that	went	
beyond	a	media-induced	change	(with	no	Dox)	at	each	point	in	the	time-course.		
	




















a	 significant	 upregulation	 in	 mRNA	 levels	 was	 identified	 in	 response	 to	 FOXG1	
overexpression	 (Figure	 3-8	 A	 and	 B).	 The	 Forkhead	 factor,	 FoxO3,	 a	 known	 tumour	
suppressor	and	previously	reported	target	of	FOXG1/SOX2	in	the	Bulstrode	et	al.	study,	
did	not	show	a	significant	change	in	expression	on	induction	of	FOXG1	(Figure	3-8	C).	
This	 suggests	 that	 either	 SOX2	 may	 play	 an	 essential	 role	 in	 the	 regulation	 FoxO3	
expression,	or	that	the	switch	to	EGF/FGF-2	reduces	FoxO3	expression	to	a	level	at	which	

















course	 (F6	 cells).	 Pink	 =	 +	 Dox	 addition,	 Blue	 =	 No	 Dox	 addition.	 Expression	 values	 were	
normalised	 to	 Gapdh	 and	 shown	 relative	 to	 the	 expression	 in	 EGF/FGF-2	 control	 (in	 which	
log2(FC)	=	0,	shown	by	the	dotted	line).		Time	zero	represents	expression	level	after	24	h	BMP4	
treatment.	Y	axis	represents	log2(FC),	equivalent	to	-ddCt	value.	Mean	+/-	SEM.	n=4	independent	






Chapter 3 | Results 
 
 94 
3.3.2 FOXG1 overexpression results in activation of epigenetic regulators 
As	described	earlier,	previous	work	found	that	while	FoxO3	loss	is	sufficient	to	enable	
cell	cycle	re-entry,	reacquisition	of	an	NSC	state	can	be	driven	only	in	combination	with	
5-Aza	 (Bulstrode	 et	 al,	 2017).	 This	 indicated	 the	 importance	 of	 epigenetic	 resetting	
during	re-acquisition	of	the	NS	cell	state	driven	by	FOXG1/SOX2	and	suggested	that	cell	
cycle	 re-entry	 and	 epigenetic	 resetting	 are	 controlled	 by	 pathways	 that	 can	 be	
uncoupled.		
We	 therefore	 searched	 for	 candidate	 epigenetic	 regulators	 that	 might	 be	 targets	 of	
FOXG1.	We	assessed	a	panel	of	six	known	epigenetic	modifiers	(Dnmt1,	Dnmt3b,	Tet3,	
Hdac7,	Ezh2	and	Chd3),	previously	uncovered	as	candidate	targets	of	FOXG1/SOX2.		All	
factors	 analysed	 were	 confirmed	 as	 significantly	 upregulated	 in	 response	 to	 FOXG1	
transgene	 induction	 in	 F6	 cells	 (Figure	 3-9).	 These	 included	 regulators	 of	 DNA	
methylation:	 DNA	 methyltransferase	 1	 (Dnmt1)	 which	 is	 known	 for	 its	 role	 in	
maintenance	 of	 established	methylation	marks,	DNA	methyltransferase	 3b	 (Dnmt3b)	
which	catalyses	de	novo	DNA	methylation,	and	Tet	methylcytosine	dioxygenase	3	(Tet3)	
which	catalyses	oxidation	of	5-methylcytosine	leading	to	loss	of	methylation.	In	addition,	
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3.3.3 Activation of DNA methylation regulators by FOXG1 may affect key 








stages	 during	 the	 FOXG1-induced	 reactivation	 process	 (RRBS	 performed	 by	 WTCRF	



















Schematic	 describing	 the	experimental	 set-up	 for	 genomic	DNA	collection.	 Genomic	DNA	was	
collected	from	FOXG1-inducible	(F6)	adult	mouse	NS	cells:	in	NS	cell	media	(EGF/FGF-2),	after	
treatment	with	BMP4	for	24	hr,	4	days	or	10	days,	and	after	treatment	with	BMP4	for	24	hr	and	















were	significantly	enriched	 in	 the	vicinity	of	PRC	target	genes	previously	reported	 in	
mouse	NS	cells,	embryonic	stem	cells	and	brain	tissue	(Figure	3-12	A	and	B)	(Meissner	
et	al,	2008;	Bulstrode	et	al,	2017).	This	included	differential	methylation	near	a	Foxg1-
binding	 site	 at	 the	 promoter	 of	 FoxO3,	 a	 known	 tumour	 suppressor	 and	 validated	
downstream	transcriptional	target	of	FOXG1/SOX2	(Figure	3-12	C),	and	also	near	 the	
promoter	 of	 the	 developmental	 gene,	 Pou3f1/Oct6	 (data	 not	 shown).	 Unfortunately,	
significant	differences	in	methylation	profile	were	not	observed	following	induction	of	
FOXG1	 overexpression	 for	 4	 days;	 this	 is	 most	 likely	 due	 to	 the	 low	 efficiency	 of	
reactivation,	with	only	a	small	subset	of	cells	returning	to	an	NS	cell	state	every	24	h.		
These	 results	 suggested	 that	 through	 transcriptional	 activation	 of	 DNA	 methylation	














Figure	 3-11	 |	 RRBS	 reveals	 BMP4-induced	 DMRs	 are	 enriched	 in	 the	 vicinity	 of	
developmental	transcription	factors.		
Analysis	and	figures	by	Dr	Duncan	Sproul.	Published	in	Genes	and	Development	(Bulstrode	et	al,	
2017).	 Analysis	 of	 GO	 terms	 associated	 with	 genes	 located	 in	 the	 vicinity	 of	 differentially	
methylated	 regions	 (DMRs)	 identified	 by	 RRBS.	 Shown	 are	 the	 top	 10	 significantly	 enriched	
Biological	 Process	 and	Molecular	 Function	GO	 terms	 associated	 for	BMP-induced	DMRs	after	
either	(A)	24	h	or	(B)	10	days	in	differentiation	conditions.	Log10	Benjami-Hochberg	adjusted	p-
values	 from	Fisher’s	 exact	 tests	 versus	 the	 background	set	are	 plotted.	 (Blue)	BMP-increased	
methylation;	(orange)	BMP-decreased	methylation.	 



























factor	 unresponsive,	 obtain	 an	 astrocytic	morphology,	 upregulate	 astrocytic	markers	
such	as	Gfap	and	Aqp4,	and	downregulate	radial	glia/NS	cell	markers	such	as	Nestin	and	
Olig2	 (Figures	 3-2	 and	 3-3).	 We	 therefore	 initially	 viewed	 them	 as	 terminally	
differentiated.	However,	the	exact	state	of	these	cells	is	difficult	to	define	due	to	the	lack	
of	 definitive	 markers	 and	 transcriptional	 differences	 that	 can	 distinguish	 terminally	
differentiated	GFAP-expressing	astrocytes	 from	quiescent	 type	B	SVZ	NS	cells	 (which	




This	 suggests	 in	 vitro	 NS	 cells	 may	 lie	 along	 a	 continuous	 spectrum	 of	 states	 from	
dormant	 quiescent,	 activated	 quiescent	 (primed	 for	 cell	 cycle	 re-entry)	 to	 actively	
proliferating,	similar	to	that	observed	in	vivo	in	the	mouse	SVZ	(Figure	1-2B)	(Dulken	et	
al,	 2017).	 Indeed,	 after	 24	 h	 BMP4	 treatment,	we	 observe	 a	minimal	 level	 of	 colony	
formation	 in	 no	 Dox	 controls	 following	 10	 days	 of	 exposure	 to	 the	 growth	 factors	









treatment,	 we	 have	 considered	 the	 changes	 induced	 by	 FOXG1	 overexpression,	 in	
















(Gómez-López	 et	 al,	 2011;	 Bulstrode	 et	 al,	 2017).	 FOXG1	 is	 however	 required	 for	
proliferation	in	vivo,	where	EGF/FGF-2	signals	may	be	limited,	and	there	are	many	pro-
differentiation	or	cytostatic	cues	(Figure	1-7).	 In	contrast	SOX2	alone	was	previously	
found	 to	 be	 unable	 to	 drive	 an	 NSC-like	 phenotype	 (Bulstrode,	 2015).	We	 therefore	
concluded	that,	while	SOX2	 is	essential	 for	sustained	proliferation	of	NS	and	GNS	cell	
lines,	 FOXG1	 is	 not;	 instead	 it	 has	 a	 key	 role	 in	protecting	 the	NS	 cell-like	 state	 and	
enabling	exit	from	the	dormant	quiescent	or	differentiated	state	(Bulstrode	et	al,	2017).	
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To	 further	 explore	 the	 mechanism	 by	 which	 FOXG1	 overexpression	 enforces	 a	







Notably,	 in	 contrast	 to	 a	 previously	 validated	 FOXG1	 target,	 the	 tumour	 suppressor	
FoxO3,	these	factors	were	upregulated	in	response	to	elevated	FOXG1.	FOXG1’s	role	in	












of	 epigenetic	 regulators	 in	 response	 to	 FOXG1	 induction.	 Enzymes	 controlling	 DNA	
methylation,	 such	 as	 Dnmt3b	 and	 Tet3,	 and	 chromatin	 modifiers,	 such	 as	 Chd3,	 all	
exhibited	an	upregulation	in	expression	(Figure	3-9).	Subsequent	RRBS	analysis	on	cells	




vicinity	 of	 PRC	 target	 genes	 (Figures	 3-11	 and	 3-12).	 This	 included	 differential	
methylation	near	a	Foxg1-binding	site	at	the	promoter	of	FoxO3,	a	known	target	of	Foxg1	
(Figure	3-12	C).	Together	these	results	suggest	that,	through	transcriptional	activation	
of	 DNA	 methylation	 regulators,	 induction	 of	 high	 FOXG1	 levels	 may	 aid	 the	
reconfiguration	of	DNA	methylation	changes	imposed	during	BMP4	treatment	back	to	an	
NS	cell-like	state.	 Indeed,	 this	FOXG1-induced	reactivation	of	d-qNSCs	is	analogous	 to	
direct	cellular	reprogramming	 in	vitro,	 in	which	 the	re-establishment	of	an	 immature	
open	chromatin	state,	through	global	resetting	of	histone	and	DNA	modification	patterns,	






underestimation	 of	 key	 transcriptional	 changes	 with	 underlying	 functions	 in	 driving	




of	 the	 GSK3	 inhibitor	 Chiron,	 to	 enhance	 FOXG1-induced	 d-qNSC	 reactivation	
(F.Robertson,	 in	preparation).	However,	 caution	would	need	 to	be	 taken	 to	delineate	
changes	 due	 to	 FOXG1	 or	Wnt	 signalling.	 In	 addition,	 FOXG1	 also	 has	 reported	DNA	
binding-independent	actions,	therefore	changes	in	methylation	may	not	always	coincide	
with	TF	binding.	Alternatively,	in	future	the	generation	of	FOXG1-ERT2	fusion	transgenes	
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suggests	 FOXG1	 is	 functionally	 important	 in	 sustaining	 a	 proliferative	 state	 with	 an	




In	 the	next	chapter,	 I	 focus	on	exploring	the	 functional	 importance	of	 two	of	FOXG1’s	













Figure	3-13	 |	FOXG1	enforces	an	NS	cell	 identity	 through	transcriptional	control	of	cell	
cycle	and	epigenetic	regulators.		
Working	 model	 for	 FOXG1	 function	 in	 GSCs	 (adapted	 from	 Bulstrode	 et	 al,	 2017.).	 Green	
=astrocytic	d-qNSC,	blue	=	radial	glia-like	proliferative	NS	cell.		
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CHAPTER 4  









and	 FoxO6.	 These	 factors	 have	 pleiotropic	 roles	 in	 proliferation,	 metabolism,	
differentiation	and	apoptosis;	 they	have	hence	been	 implicated	 in	ageing	 and	 cancer.		
However,	FoxO6	is	the	most	recently	identified	FoxO	gene	and	the	least	well-studied.	It	
also	has	some	distinct	characteristics	compared	to	its	other	family	members.	While	the	
activity	of	all	FoxO	 family	members	 is	regulated	by	growth	 factor	signalling	via	PKB-
mediated	 phosphorylation,	 unlike	 the	 other	 family	 members	 phosphorylation	 status	
does	 not	 regulate	 FoxO6	 nuclear-cytoplasmic	 shuttling.	 FoxO6	 remains	 localised	
constitutively	to	the	nucleus,		even	in	the	inactive	form	(van	der	Heide	et	al,	2005;	Jacobs	
et	al,	2003).	
In	 addition,	while	 other	 FoxO	 factors	 are	 relatively	 ubiquitously	 expressed,	FoxO6	 is	
predominantly	 expressed	 in	 the	 CNS	 of	 mammals	 (Salih	 et	 al,	 2012;	 Hoekman	 et	 al,	
2006).	Similarly	 to	FOXG1,	FoxO6	 is	expressed	at	high	 levels	 in	 the	developing	 foetal	
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FoxO3	 has	 been	 well-described	 in	 preserving	 quiescence	 and	 preventing	 premature	
differentiation	of	NS	cells	(Renault	et	al,	2009).	The	clinical	relevance	of	FoxO6	in	cancer	
biology	is	not	fully	understood;	however,	its	levels	have	been	shown	to	be	upregulated	
in	 various	 cancer	 types,	 suggesting	 an	 oncogenic	 role.	 For	 example,	 FoxO6	 has	 been	
reported	to	promote	proliferation	and	regulate	c-Myc	expression	in	gastric	cancer	cells	
(Qinyu	 et	 al,	 2013),	 whereas	 in	 lung	 cancer	 it	 has	 been	 reported	 to	 induce	 Sox2	












genes	 significantly	 associated	with	overall	 survival	 in	GBM	 (Bao	et	 al,	 2013;	 Li	et	 al,	
2016).	Both	Chd3	and	another	core	component	of	the	NuRD	complex,	Chd4,	can	interact	
with	 transcription	 factors.	 For	 example,	 the	 co-repressor	 NAB2	 can	 bind	 to	 the	 C-
terminal	 domain	 of	 Chd3	 to	 co-repress	 trans-activators	 involved	 in	 prostate	 cancer	
progression	 (Srinivasan	 et	 al,	 2006).	 Association	 of	 Chd4	 to	 the	 transcription	 factor	









reactivate	 tumour	 suppressors	 and	 other	 transcription	 factors	 aberrantly	 silenced	 in	
cancer		(Safa	et	al,	2016).	Furthermore,	addition	of	inhibitors	of	epigenetic	modifiers	to	




human	 models	 of	 GBM	 described	 in	 the	 introduction,	 along	 with	 CRISPR/Cas9	
technology,	to	validate	whether	FoxO6	and	Chd3	are	downstream	targets	of	FOXG1	in	
alternative	contexts.	
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4.2 Validation of FoxO6 as a downstream target of FOXG1 
4.2.1 FoxO6 mRNA expression increases in response to elevated FOXG1 in 
proliferating NSCs 
While	 reactivation	 of	 astrocytic	 d-qNSCs	 provides	 a	 convenient	 system	 to	 identify	
FOXG1’s	 transcriptional	 targets,	 it	 is	 also	 important	 to	 ascertain	 whether	 these	
transcriptional	targets	are	regulated	in	alternative	contexts.	For	example,	does	FOXG1	
also	 regulate	 FoxO6	 in	 proliferating	 NS	 cells?	 If	 so,	 this	 may	 suggest	 a	 role	 in	 both	
initiating	and	maintaining	a	proliferative	NS	cell	state.	To	answer	this	question,	FoxO6	





FOXG1	 expression	 with	 Dox,	 the	 absolute	 normalised	 expression	 was	 higher	 in	 F6,	
possibly	 leading	 to	 increased	 FoxO6	 activation.	 FoxO6	 is	 therefore	 a	 transcriptional	
target	of	FOXG1	in	both	proliferating	NSCs,	as	well	as	during	d-qNSC	reactivation.	
	




Figure	4-1	 |	FoxO6	mRNA	 levels	are	 increased	 in	 response	 to	 FOXG1	overexpression	 in	
proliferating	NSCs.		
(A)	 Schematic	of	experimental	 set-up:	adult	mouse	NS	cell	 lines	(‘F6’	and	 ‘F11-19’)	with	Dox-
inducible	FOXG1	expression	were	grown	in	NS	cell	media	(EGF/FGF-2)	with	or	without	Dox	for	
24h.	 (B)	 qRT-PCR	 analysis	 of	 FOXG1	 mRNA	 levels	 in	 F6	 and	 F11-19.	 n=2	 independent	
experiments.	 Each	 data	 point	 shows	 the	 mean	 of	 one	 experiment,	 performed	 in	 technical	
duplicates.	 (C)	 qRT-PCR	 analysis	 of	 FoxO6	mRNA	 levels	 in	 F6	 and	 F11-19.	 n=3	 independent	
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4.2.2 FOXO6 protein levels increase in response to elevated FOXG1 
To	validate	that	FOXG1	overexpression	leads	to	upregulation	of	FOXO6	at	the	protein	
level,	 several	 anti-FOXO6	 antibodies	 were	 tested	 by	 ICC	 and	 Western	 blotting.	
Unfortunately,	out	of	three	commercial	antibodies	tested,	none	showed	specific	staining	









A).	 We	 chose	 an	 HA	 tag,	 which	 is	 commonly	 used	 for	 biochemical	 and	 ICC	 studies.	
Successful	 insertion	 of	 the	 HA	 tag	 was	 confirmed	 using	 PCR	 genotyping	 of	 the	 bulk	
transfected	population	(Figure	4-2	B).	FOXO6-HA	expression	was	not	visible	by	ICC	or	
Western	 blotting	 in	 proliferating	NS	 cells,	 consistent	with	 the	 lower	 levels	 of	 mRNA	
detected	 by	 qRT-PCR	 (Figure	 4-1).	 However,	 following	 addition	 of	 Dox	 and	 hence	















HA	 tag	 at	 the	 3’	 end	 of	 FoxO6.	 Clonal	 F6	 FoxO6-HA	 cell	 line	 shown	 as	 positive	 control.	 (C)	
Schematic	describing	treatment	of	F6	FoxO6-HA	bulk	population	for	assessment	of	FOXO6	protein	
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a	 wild-type	 Cas9-2A-mCherry	 expression	 vector,	 these	 sgRNAs	 were	 transiently	
delivered	into	IENS-GFP	by	nucleofection.	Successful	transfectants	were	isolated	using	





of	 the	 two	 resulting	 ends	would	 result	 in	 the	 loss	 of	 approximately	 1.3	 kb	 of	 coding	
sequence	and	most	likely	a	frameshift.	Out	of	60	clones	analysed,	15	showed	evidence	of	
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overexpression	 and	 Ink4a/Arf	 deletion)	 was	 created	 in	 the	 lab	 by	 Dr	 Ester	 Gangoso	
(Figure	4-3	F).	This	transformed	cell	line,	termed	FF-IEK,	was	derived	from	adult	mouse	
NS	cell	line	‘FF’,	derived	from	the	SVZ	of	homozygous	adult	Foxg1fl/fl	mice	by	H.Bulstrode	
(mice	 provided	 V.	 Fotaki;	 originally	produced	 by	 the	 Fischell	 lab,	 (Miyoshi	 &	Fishell,	
2012).	 Addition	 of	 Cre	 recombinase	 to	 these	 cells	 resulted	 in	 deletion	 of	 Foxg1,	 as	
confirmed	by	Western	blotting	(Figure	4-3	G).		
qRT-PCR	analysis	was	performed	in	these	two	independent	cell	lines	(IENS-GFP	and	FF-
IEK)	 alongside	 their	 respective	Foxg1	 knockout	 clones.	 In	both	 cases,	 this	 revealed	 a	
trend	for	downregulation	of	FoxO6	mRNA	levels	upon	Foxg1	deletion	(Figure	4-4).	IENS-
GFP	Foxg1	KO	cell	lines	58	and	59	showed	a	mean	6-7-fold	(84-86%)	decrease	in	FoxO6	





















































compared	 to	 parental	 IENS-GFP	 (in	 which	 in	 which	 log2(FC)	 =	 0).	 Expression	 values	 were	
normalised	to	Gapdh.	Y	axis	represents	 log2(Fold	change),	equivalent	to	-ddCt	value.	Mean	+/-	
SEM.	 n=3	 independent	 experiments.	 Each	 data	 point	 shows	 the	 mean	 of	 one	 experiment,	
performed	in	technical	duplicates.	(B)	qRT-PCR	analysis	of	FoxO6	mRNA	levels	in	FF-IEK	Foxg1-/-	
cells	 (Cre	 addition),	 compared	 to	 parental	 ‘FF-IEK’	 (in	 which	 in	 which	 log2(FC)	 =	 0).	 n=5	
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4.2.4 FoxO6 is not essential for NS cell proliferation in EGF/FGF-2 or response 
to BMP4 signalling.  
Following	validation	that	FoxO6	is	a	downstream	target	of	FOXG1	in	multiple	contexts,	
we	 next	 wanted	 to	 define	 whether	 these	 elevated	 levels	 are	 necessary	 to	 enforce	 a	
proliferative	NS-cell	like	identity.	Gene	targeting	to	delete	FoxO6	from	adult	mouse	NS	
(ANS4)	 cells	was	 previously	 performed	 by	 Claudia	 Garcia-Diaz	 using	 a	 CRISPR/Cas9	
strategy	described	in	Bressan	et	al.	(2017).		A	clonal	FoxO6	knockout	cell	line	was	derived	
(clone	53).	 In	one	allele,	exon	1	of	FoxO6	 is	 replaced	by	an	EF1a-puromycin	cassette,	
whereas	 the	 remaining	 allele	 is	 targeted	 by	 a	 sgRNA	 resulting	 in	 NHEJ	 and	 indel	






could	 not	 be	 performed.	 qRT-PCR	 analysis	 confirmed	 negligible	FoxO6	 expression	 in	
comparison	to	the	parental	control	(Figure	4-5	C);	FoxO6	KO	clone	53	showed	an	~	55-
fold	(98%)	decrease	in	expression.		
Analysis	 of	 the	 growth	 kinetics	 of	 FoxO6	 KO	 cells	 in	 EGF/FGF-2	 showed	 a	 modest	











replicates,	 therefore	 it	 was	 not	 possible	 to	 conclude	 whether	 deletion	 of	 FoxO6	
significantly	 alters	 the	 efficiency	 of	 colony	 formation	 (Figure	 4-6	 F).	 	 These	 results	
indicate	 that	 FoxO6	 is	 not	 essential	 for	 proliferation	 or	 colony	 formation	 of	 NSCs	 in	
EGF/FGF-2.	
Next	we	assessed	the	ability	of	FoxO6	KO	cells	to	respond	to	BMP4	signalling.	ICC	analysis	
revealed	 both	 parental	 ANS4	 and	 FoxO6	 KO	 53	 cells	 show	 a	 decrease	 in	 Nestin	 and	









































parental,	black	=	FoxO6	KO	53.	 	Mean	+/-	SD,	n=3	 technical	 replicates.	Representative	of	n=4	
independent	experiments.	(B)	Bar	graph	showing	the	gradient	of	the	linear	portion	of	the	logistic	
growth	curve	(%/h).	Mean	+/-	SEM,	n=4	independent	experiments.	Each	data	point	shows	the	
mean	 of	 one	 experiment.	 Two-tailed	 paired	 Student’s	 t-test.	 (*	 P	 ≤	 0.05).	 (C)	 Representative	
fluorescent	 images	 of	 EdU	 incorporation	 after	 24	 h	 pulse	 on	 day	 3	 of	 growth	 analysis	 (ANS4	
parental	and	FoxO6	KO	53	cells).	Scale	bar:	100	µm.	(D)	Quantification	of	%	EdU	positive	cells	
after	24	h	pulse	on	day	3	of	growth	analysis.	Mean	+/-	SEM,	n=2	independent	experiments.	Each	
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were	 normalised	 to	 Gapdh	 and	 shown	 relative	 to	 the	 expression	 in	 parental	 ANS4	 cells	 in	
EGF/FGF-2	(in	which	log2(FC)	=	0,	shown	by	the	dotted	line).	Y	axis	represents	log2(Fold	change),	
equivalent	to	-ddCt	value.	Graph	shows	Mean	+/-	SEM.	n=2	independent	experiments.	Each	data	
point	 shows	 the	 mean	 of	 one	 experiment,	 performed	 in	 technical	 duplicates.	 Statistics	 were	
calculated	from	ddCt	values.	Two-tailed	Student’s	t-test.	*	P	≤	0.05	(E)	Quantification	of	%	cells	
with	EdU	incorporation	after	treatment	with	BMP4	or	EGF/FGF-2	for	1d,	followed	by	a	24	h	EdU	
pulse	 in	 EGF/FGF-2	 (ANS4	 parental	 and	 FoxO6	 KO	 53).	 Mean	 +/-	 SEM.	 n=2	 independent	
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4.2.5 FOXG1-induced reactivation of dormant quiescent NSCs is inhibited in 
FoxO6 null cells 
With	 the	 knowledge	 that	 FoxO6	 loss	 does	 not	 have	 a	 significant	 negative	 effect	 on	
proliferation	in	EGF/FGF-2	or	BMP4	induction	of	an	astrocytic	d-qNSC	state,	we	next	set	
out	 to	 determine	 if	 loss	 of	 FoxO6	 affects	 the	 efficiency	 of	 FOXG1-induced	 colony	
formation.	Both	ANS4	and	FoxO6-null	mouse	NS	cells	(clone	53)	were	transfected	with	
expression	vectors	 encoding	 the	PiggyBac	 transposase,	Tet-On	3G	 transactivator	 and	











able	 to	 form	 colonies	 upon	 induction	 of	 FOXG1.	 However,	 FoxO6-null	 cells	 showed	
significantly	 reduced	 colony	 formation,	 despite	 their	 slightly	 higher	 levels	 of	 FOXG1	
transgene	 induction	 (Figure	 4-8	 E-G).	 This	 result	 indicates	 that	FoxO6	may	 be	 a	 key	
downstream	effector	of	FOXG1	in	driving	d-qNSCs	back	into	cycle.		
ICC	analysis	confirmed	that,	unlike	ANS4,	levels	of	Nestin	were	not	highly	upregulated	in	
the	FoxO6	 KO	 cells	 on	 addition	of	Dox	 (compared	 to	no	Dox	 control)	 (Figure	4-9	A).	
However,	the	FoxO6	KO	cells	did	show	a	change	in	morphology	on	induction	of	FOXG1,	









FoxO6	 KO	 cells	 are	 able	 to	 respond	 in	 some	 form	 to	 FOXG1	 overexpression,	 FoxO6	
expression	is	required	for	BMP4	treated	cells	to	transition	to	a	highly	proliferative	NS	
cell-like	state. 






cells	with	Dox-inducible	 FOXG1	 expression	 (as	 shown	 in	 Figure	 3-4).	 In	 panels	 (B)-(H)	ANS4	
parental	and	FoxO6	KO	53	refer	 to	 transfected	cell	populations	with	Dox-inducible	FOXG1-V5	
overexpression.	Figure	legend	continued	overleaf.	







independent	 experiments.	 Each	 data	 point	 shows	 the	mean	 of	 one	 experiment,	 performed	 in	












10-15	days	 (ANS4	parental	 or	FoxO6	KO	53).	 Graph	 shows	Mean	+/-	SEM,	 n=	 4	 independent	
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4.2.6 Analysis of FOXO6 expression in patient-derived GNS cells 
Following	 the	 validation	of	 a	 functional	 role	 for	FoxO6	 in	quiescent	mouse	NSCs,	we	
wanted	to	explore	its	role	in	human	GBM	using	patient-derived	GNS	cells.	As	detailed	in	




Through	 the	 Cancer	 Research	 UK	 Glioma	 Cellular	 Genetics	 Resource	 (GCGR)	
(www.gcgr.org.uk),	a	series	of	new	patient-derived	GNS	cell	lines	were	available	(Figure	
4-10	A),	each	of	which	had	been	profiled	alongside	its	parental	tumour	tissue	to	ensure	
no	 transcriptional	 or	 karyotypical	 corruptions	 during	 culture.	 Firstly,	 using	Western	
blotting	we	confirmed	that	FOXG1	protein	levels	were	elevated	in	GNS	cells	(G7,	G301-
B,	G313,	G317,	G325,	G326,	G327,	G328	and	G330),	compared	to	normal	human	foetal	
NS	 cell	 lines	 (CB152	 and	 CB11130)	 (Figure	 4-10	B).	 ICC	 and	 qRT-PCR	analysis	 then	
showed	 that	 each	 cell	 line	 had	 variable	 levels	 of	 FOXG1	 expression,	 compared	 to	 an	
established	and	widely	used	GNS	cell	line,	G7	(Figure	4-10	C	and	D).		








plasmid-based	method	used	 for	Foxg1	deletion	 in	mouse	 IENS	cells	 (Figure	4-3),	 this	




and	 ‘off’	 rates,	 as	 well	 as	 no	 requirement	 for	 plasmid	 construction.	 Following	










































(A)	 Experimental	 strategy	 for	 FOXG1	 deletion	 in	 human	 GNS	 G313	 cells	 using	 a	 Cas9	








represents	 log2(Fold	 change),	 equivalent	 to	 -ddCt	 value.	 Graph	 shows	 Mean	 +/-	 SEM.	 n=3	
independent	 experiments.	 Each	data	 point	 shows	 the	mean	 of	 one	 experiment,	 performed	 in	
technical	duplicates.	Statistics	were	calculated	from	ddCt	values.	Two-tailed	one	sample	t-test.	
	




Figure	 4-12	 |	 No	 correlation	 is	 found	 between	 FOXG1	 and	 FOXO6	 expression	 levels	 in	
patient-derived	GNS	cell	lines	and	matched	tissue	samples.		
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4.3 Validation of Chd3 as a downstream target of FOXG1 
4.3.1 Chd3 expression increases in response to elevated FOXG1 in 
proliferating NSCs 




cell	 media	 (EGF/FGF-2).	 The	 DNA	 methylation	 regulators,	 Dnmt1/3a/3b,	 showed	

















Figure	4-13	 |	Chd3	mRNA	levels	 are	 increased	 in	 response	 to	 FOXG1	overexpression	 in	
proliferating	NSCs.		
(A)	 Schematic	of	experimental	 set-up:	adult	mouse	NS	cell	 lines	(‘F6’	and	 ‘F11-19’)	with	Dox-
inducible	FOXG1	overexpression	were	grown	in	NS	cell	media	(EGF/FGF-2)	with	or	without	Dox	
for	 24	 h.	 (B)	 qRT-PCR	 analysis	 of	 FOXG1	mRNA	 levels	 in	 F6	 and	 F11-19.	 n=2	 independent	
experiments.	 Each	 data	 point	 shows	 the	 mean	 of	 one	 experiment,	 performed	 in	 technical	
duplicates.	(C)	qRT-PCR	analysis	of	Chd3,	Tet3,	Dnmt1,	Dnmt3b	and	Dnmt3a	mRNA	levels	in	F6	
and	 F11-19.	 n=2	 or	 3	 independent	 experiments.	 Each	 data	 point	 shows	 the	 mean	 of	 one	
experiment,	performed	in	technical	duplicates.	All	expression	values	were	normalised	to	Gapdh	
and	shown	relative	to	the	expression	in	EGF/FGF-2	-Dox	(in	which	log2(FC)	=	0).	Y	axis	represents	
log2(Fold	 change),	 equivalent	 to	 -ddCt	 value.	 Graph	 shows	 Mean	 +/-	 SEM.	 Statistics	 were	
calculated	from	ddCt	values.	Two-tailed	one-sample	Student’s	t-test.	*	P	≤	0.05,	**	P	≤	0.01).		
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4.3.2 Chd3 mRNA is reduced following Foxg1 knockout in mouse GSCs 
To	further	validate	Chd3	as	a	transcriptional	target	of	FOXG1,	qRT-PCR	analysis	of	Chd3	
mRNA	 levels,	 alongside	 other	 epigenetic	 regulators,	 was	 performed	 in	 the	 two	
independent	mouse	GBM	model	cell	lines	shown	in	Figure	4-3	(IENS-GFP	and	FF-IEK).	
While	Tet3	 levels	were	not	altered	upon	Foxg1	 deletion	 from	 IENS	 cells,	Chd3	mRNA	
levels	were	significantly	downregulated	in	both	clonal	Foxg1	null	cell	lines	(Figure	4-14).	




(adult	 or	 postnatal),	 using	 different	 methods	 for	 Ink4a/Arf	 deletion	 (CRISPR/Cas9-























performed	 in	 technical	 duplicates.	 (B)	 qRT-PCR	 analysis	 of	 Chd3,	 Tet3,	 Dnmt1,	 Dnmt3b	 and	
Dnmt3a	mRNA	 levels	 in	FF-IEK	Foxg1-/-cells	 (Cre	addition),	 compared	 to	parental	 ‘FF-IEK’	 (in	
which	 log2(FC)	 =	 0).	 n=3	 independent	 experiments.	 Each	 data	 point	 shows	 the	mean	 of	 one	















































































In	 this	chapter,	we	have	 found	FoxO6	and	Chd3	 to	act	as	downstream	transcriptional	
targets	 of	 FOXG1	 in	 multiple	 contexts.	 FoxO6	 showed	 significant	 fold	 changes,	 with	





FoxO6	 analyses	 were	 further	 limited	 by	 the	 lack	 of	 commercially	 available	 protein-
specific	 antibodies.	 However,	 increased	 protein	 levels	 upon	 induction	 of	 FOXG1	 in	
proliferating	mouse	NS	cells	was	confirmed	with	the	aid	of	CRISPR/Cas9-mediated	gene	
epitope	tagging	(Figure	4-2),	a	technology	I	discuss	in	greater	depth	in	the	next	chapter.	
These	promising	results	 led	us	 to	 investigate	whether	FoxO6	 is	required	 for	FOXG1’s	
function	in	driving	the	reactivation	of	astrocytic	d-qNSCs.	This	revealed	that	FoxO6	KO	















cells	 to	 BMP4	 treatment	 showed	 no	 significant	 differences	 under	 our	 experimental	
conditions	(Figure	4-7).	While	not	statistically	significant,	a	couple	of	EdU-positive	ANS4	
cells	were	noted	following	24	h	BMP4	treatment	and	return	to	EGF/FGF-2,	compared	to	
none	 in	 the	FoxO6	KO	cells	 (Figure	4-7	E).	FoxO6	KO	cells	also	showed	slightly	 lower	
levels	of	Nestin	mRNA	after	24h	BMP4	treatment	(Figure	4-7	D).	It	is	possible	that	high	
FoxO6	levels	act	to	restrict	differentiation	commitment,	and	deletion	of	FoxO6	results	in	
a	 ‘deeper’	 dormant	 quiescent	 state.	 However,	 this	 is	 difficult	 to	 establish	 due	 to	 the	
current	lack	of	markers	distinguishing	quiescent	NS	cells	and	mature	astrocytes.	Further	
markers	 or	 prolonged	 EdU	 exposure	 may	 help	 to	 establish	 if	 FoxO6	 loss	 positively	





suggest	a	 role	of	 elevated	FOXO6	 in	driving	 cancer	 cell	proliferation	 and	progression		
(Qinyu	et	al,	2013;	Rothenberg	et	al,	2015;	Wang	et	al,	2017a;	Lallemand	et	al,	2018).	In	
EGF/FGF-2	we	observed	only	a	small	proliferation	defect	on	FoxO6	deletion	from	ANS4	
cells	 (Figure	 4-6	 A-D).	 However,	 basal	 FoxO6	 levels	 are	 low	 in	 these	 conditions;	 we	
therefore	cannot	discount	a	role	for	high	FOXO6	in	driving	cell	cycle	re-entry	of	dormant	
quiescent	 NSCs	 or	 in	 maintaining	 a	 proliferative	 state	 in	 the	 presence	 of	 pro-
differentiation	cues.		
FoxO6	 also	 has	 reported	metabolic	 roles	 in	 the	 liver	 and	 skeletal	muscle	 (Kim	 et	 al,	
2011a;	Chung	et	al,	2013);	it	 is	therefore	plausible	that	high	FoxO6	levels	may	aid	re-




deregulation	 of	 cellular	 energetics	 is	 one	 of	 the	 hallmarks	 of	 cancer	 proposed	 by	
Hanahan	and	Weinburg	(Hanahan	&	Weinberg,	2011)	and	a	switch	to	aerobic	glycolysis	




in	 cancer	 whose	 overexpression	 drives	 cell	 cycle	 progression	 and	 several	 metabolic	
changes	(Peck	et	al,	2013).		
In	 contrast,	 FoxO6	 has	 been	 reported	 to	 promote	 cell	 proliferation	 in	 gastric	 cancer	
through	 induction	of	 c-Myc	 expression	 (Qinyu	et	 al,	 2013).	Notably,	 in	Chapter	3	we	
observed	FOXG1-induced	upregulation	of	N-Myc	in	d-qNSCs	(Figure	3-8	B).	We	therefore	
speculate	that,	in	comparison	to	FoxO3,	FoxO6	may	have	oncogenic	roles	in	altering	cell	
metabolism,	perhaps	 controlling	 a	 shift	 between	oxidative	 and	glycolytic	metabolism	
needed	to	transition	to	a	highly	proliferative	state.	A	shift	towards	glycolytic	metabolism	
has	 recently	 been	 suggested	 to	 play	 a	 pivotal	 role	 in	 acquisition	 of	 cancer	 stemness	
(Menendez	&	 Alarcon,	 2014).	 Silencing	 of	FoxO6	 has	 recently	 been	 shown	 to	 inhibit	
proliferation	 and	 glycolysis	 in	 colorectal	 cancer	 cells	 (Li	 et	 al,	 2019).	 This	 was	
accompanied	 by	 loss	 of	 activation	 of	 PI3K/Akt/mTor	 signalling;	 furthermore	 mTOR	
signalling	has	been	shown	to	control	glycolytic	metabolism	in	GBM	through	inhibition	of	
HDACs,	 leading	 to	 acetylation	 of	 FoxO1/3	 and	 subsequent	 derepression	 of	 c-Myc	
expression	 (Masui	 et	 al,	 2013).	 FOXG1	 itself	 has	 been	 implicated	 in	 regulating	
mitochondrial	functions	(Pancrazi	et	al,	2015),	suggesting	a	potential	role	for	FoxO6	in	
altering	cell	metabolism	should	be	further	explored.	
Unlike	other	epigenetic	regulators	 identified	 in	Chapter	3,	mRNA	 levels	of	Chd3	were	










Our	 results	 suggest	 that	 the	majority	of	 epigenetic	 regulators	 analysed	are	 targets	 of	
FOXG1	in	a	context-dependent	manner,	during	the	cell	fate	transition	from	a	dormant	
quiescent	 to	a	proliferative	radial-glia-like	NS	cell	state.	 In	agreement,	chromatin	and	
DNA	 methylation-related	 drivers	 have	 been	 implicated	 in	 driving	 CSC	 initiation	 in	
numerous	malignancies	(Wainwright	&	Scaffidi,	2017).	However,	epigenetic	remodelling	





The	 transcriptional	 changes	 in	 both	FoxO6	 and	Chd3,	 when	 FOXG1	 is	 upregulated	 or	
deleted	from	proliferating	GSC	models,	suggest	a	potential	role	for	both	in	maintaining	
the	GSC	state.	While	neither	showed	a	significant	correlation	with	FOXG1	levels	in	patient	
tissue	 samples	 and	 cell	 lines	 (Figures	 4-12	 and	 4-16),	 these	 studies	were	 limited	 to	
proliferation	in	EGF/FGF-2.	It	would	be	interesting	to	explore	potential	roles	of	these	
targets	 in	 initiating	 and/or	maintaining	 GNS	 cells	 under	 conditions	which	may	more	
accurately	 mimic	 the	 situation	 in	 vivo,	where	 cells	 are	 in	 a	 more	 quiescent	 and/or	
differentiating	state.			






both	 the	 relevance	 of	 the	 candidate	partner,	 H3K4	 demethylase	 JARID1B	 to	FOXG1’s	
functions,	and	new	genetic	 technologies	 to	aid	 the	discovery	of	novel	protein-protein	
interactions.	 Understanding	 the	 protein	 interactors	 of	 FOXG1,	 alongside	 its	
transcriptional	targets,	will	allow	us	to	build	a	more	complete	picture	of	how	this	master	
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CHAPTER 5  
Defining the critical protein partners of FOXG1  
5.1 Introduction  
In	Chapter	4	we	identified	the	Forkhead	factor,	FoxO6,	as	a	clear	transcriptional	target	
of	FOXG1	in	mouse	NSCs	and	GSCs.	The	early	induction	of	FoxO6	suggests	this	might	be	
via	 a	 direct	 mechanism,	 but	 this	 is	 paradoxical	 given	 FOXG1	 is	 best	 described	 as	 a	
transcriptional	repressor.	The	binding	of	co-factors	 is	one	aspect	 that	determines	 the	
regulatory	properties	of	TFs.	We	therefore	surmised	 that	understanding	FOXG1’s	key	
protein	partners	may	provide	 further	clues	 into	 its	mechanism	of	action	in	activating	
target	 genes.	 This	 was	 of	 interest,	 both	 in	 terms	 of	 improving	 our	 understanding	 of	
FOXG1’s	mechanism	of	action,	and	the	potential	therapeutic	interventions	which	could	
come	from	this	knowledge.	
FOXG1	 is	a	multi-domain	 transcription	 factor,	with	 three	published	domains:	 a	DNA-
binding	 Forkhead	 domain,	 a	 Groucho/TLE-1	 binding	 domain	 and	a	 JARID1B	 binding	
domain	(Figure	1-6).	While	both	TLE-1	and	JARID1B	have	been	shown	to	play	important	
roles	 in	 development,	 currently	 most	 studies	 have	 focussed	 on	 the	 FOXG1-TLE-1	
interaction	in	GSCs.		
Like	 TLE-1,	 JARID1B	 is	 a	 transcriptional	 co-repressor,	 acting	 primarily	 through	 its	
histone	demethylase	activity.	Indeed,	identification	of	a	FOXG1-JARID1B	interaction	was	
accompanied	 by	 the	 finding	 that	 the	 transcriptional	 repression	 activity	 of	 FOXG1	 is	
enhanced	by	co-expression	of	JARID1B,	and	mutation	of	the	interaction	motif		in	FOXG1	
abolishes	 this	 co-repression	 (Tan	 et	 al,	 2003).	 However,	 there	 are	 also	 reports	 of	
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We	 speculated	 that	 FOXG1’s	 interaction	 with	 JARID1B	 may	 facilitate	 transcriptional	
activation	 in	 several	 ways	 (Figure	 5-1).	 FOXG1	 has	 been	 reported	 to	 have	 a	 dose-
dependent	dual	 activity	 in	 two	 studies	of	Xenopus	neural	development	(Hardcastle	&	
Papalopulu,	2000;	Bourguignon	et	al,	1998);	for	example	injection	of	Xenopus	embryos	
with	a	high	dose	of	FoxG1	RNA	in	the	posterior	neural	plate	results	in	suppression	of	the	











of	 neural	 progenitor	 cell	 proliferation	 via	 sequestration	 of	 FoxO-SMAD	 complexes	
(Seoane	 et	 al,	 2004;	 Obendorf	 et	 al,	 2007;	 Hanashima	 et	 al,	 2002).	 We	 therefore	
hypothesised	 that	 elevated	 FOXG1	 may	 act	 to	 sequester	 its	 co-activators	 or	 co-
repressors,	such	as	JARID1B,	in	a	manner	termed	‘regulatory	squelching’	(Cahill	et	al,	






into	 its	 mechanism	 of	 action.	 Following	 the	 recent	 developments	 in	 CRISPR/Cas9	
technology,	 our	 laboratory	has	optimised	 a	method	 to	 tag	 endogenous	 genes	 in	both	
mouse	and	human	NS	cells	(Dewari	et	al,	2018;	Bressan	et	al,	2017);	this	provides	an	
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5.2 Investigating the importance of JARID1B to FOXG1’s function 
5.2.1 Co-immunoprecipitation experiments suggest an interaction between 
FOXG1 and JARID1B in mouse NS and human GNS cells 




performed	 with	 research	 technician,	 Carla	 Blin	 and	 Master’s	 student,	 Shruthi	
VijayKumar.	This	 antibody	was	 generated	 to	 target	 a	 tertiary	 structural	motif	 of	 the	
highly	conserved	Forkhead	binding	domain	and	detects	both	mouse	and	human	FOXG1.		
Native	 IP	 of	 FOXG1	 in	 ANS4	 mouse	 NS	 cell	 lysates	 was	 successful	 and	 showed	 an	
enrichment	 of	 FOXG1	 in	 the	 IP	 versus	 the	 input	 lane	 (Figure	 5-2	 A).	 Co-
immunoprecipitation	(co-IP)	of	JARID1B	was	observed,	with	a	band	at	~175	kDa.	An	IgG	








decided	 to	 further	 explore	 the	 role	 of	 the	 FOXG1-JARID1B	 interaction	 in	 FOXG1’s	
function.	
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should	be	at	very	 low	levels	 (Schmitz	et	al,	2011;	Albert	et	al,	2013).	 In	addition,	 the	
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catalytic	 core	 of	 JARID1B	 has	 been	 shown	 to	 extend	 beyond	 exon	 6,	with	 important	
functional	 and	 protein	 binding	 domains,	 such	 as	 JmjC	 and	 PHD	 domains	 lying	











2.	 This	 revealed	 inconsistent	 results	 between	 independent	 replicates,	 with	 both	
Jarid1bF/F	and	Jarid1b-/-	cells	able	to	form	typical	NS	cell	colonies	with	varying	efficiencies	















position	 of	 the	gene	 targeting	cassette	 for	 deletion	 of	exon	6	 in	 the	 Jarid1b	 locus	 (27	exons).	
Adapted	from	(Schmitz	et	al,	2011).	(B)	Overview	of	experimental	strategy	used	to	delete	Jarid1b	
exon	 6	 from	mouse	 E12.5	 NSCs.	 Adapted	 from	 (Schmitz	 et	 al,	 2011).	 (C)	 PCR	 genotyping	 to	






Y	 axis	 represents	 log2(Fold	 change),	 equivalent	 to	 -ddCt	 value.	 Graph	 shows	 Mean	 +/-	 SEM.	
Statistics	were	calculated	from	ddCt	values.	Two-tailed	one	sample	Student’s	t-test.	**	P	≤	0.01.	
(F)	Western	blot	analysis	of	 JARID1B	expression	 in	 Jarid1bF/F	 (-4OHT)	and	 Jarid1b-/-	 (+4OHT)	
cells	using	DAIN78	antibody.	JARID1B	band	at	~175	kDa	is	indicated	by	the	arrow.	GAPDH	was	
used	as	a	housekeeping	loading	control.		












of	 %	 EdU	 positive	 cells	 after	 24	 h	 pulse	 on	 day	 3	 of	 growth	 analysis.	 Mean	 +/-	 SEM,	 n=4	
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cell	 lines	decrease	Nestin	 and	Olig2	mRNA	 levels	 and	 increase	Gfap	 and	Aqp4	mRNA	
levels	on	treatment	with	BMP4	for	1	day.	No	significant	differences	in	expression	levels	
of	these	markers	were	found	between	Jarid1bF/F	and	Jarid1b-/-	cells	in	EGF/FGF-2	or	after	
BMP4	 treatment	 (Figure	 5-5	 C	 and	 D).	 Finally,	 assessment	 of	 EdU	 incorporation	
following	BMP4	treatment	for	1	day	and	a	24	h	EdU	pulse	in	EGF/FGF-2	revealed	that	







no	 significant	 negative	 impact	 on	 the	 cytostatic	 BMP4	 response	 of	 mouse	 NSCs.	 As	
described	in	section	3.4,	we	term	these	BMP4-treated	NSCs	as	d-qNSCs.	

















shows	Mean	+/-	SEM.	n=3	 independent	experiments.	Each	data	point	 shows	 the	mean	of	one	
experiment,	performed	in	technical	duplicates.	Statistics	were	calculated	from	ddCt	values.	(E)	
Quantification	of	%	cells	with	EdU	incorporation	after	treatment	with	BMP4	or	EGF/FGF-2	for	1d,	
followed	by	a	24	h	EdU	pulse	in	EGF/FGF-2	 (Jarid1bF/F	(-4OHT)	and	 Jarid1b-/-	 (+4OHT)	cells).	
Mean	+/-	SEM.	n=3	independent	experiments.	Each	data	point	shows	the	mean	of	one	experiment,	
performed	in	technical	triplicates.	Two-tailed	Student’s	t-tests.	
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5.2.4 The presence of JARID1B is not required for FOXG1-induced 




and	 Jarid1b-/-	 (+4OHT)	 cells	 were	 transfected	 with	 expression	 vectors	 encoding	 the	
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and	shown	relative	 to	 the	expression	 in	Jarid1bF/F	 (-4OHT)	cells	 in	EGF/FGF-2	 -Dox	 (in	which	
log2(FC)	=	0).	Y	axis	represents	log2(Fold	change),	equivalent	to	-ddCt	value.	Mean	+/-	SEM,	n=4	
independent	 experiments.	 Each	data	 point	 shows	 the	mean	 of	 one	 experiment,	 performed	 in	
technical	duplicates.	Two-tailed	paired	t-test.	*	P	≤	0.05.	(C)	qRT-PCR	analysis	of	FOXG1	mRNA	
expression	in	Jarid1bF/F	(-4OHT)	and	Jarid1b-/-	(+4OHT)	cells	after	treatment	with	EGF/FGF-2	or	
BMP4	 for	24h	and	return	 to	EGF/FGF-2	with	or	without	Dox	addition	 for	4	days.	 	Expression	
values	were	normalised	to	Gapdh	and	shown	relative	to	the	expression	in	Jarid1bF/F	(-4OHT)	cells	
in	EGF/FGF-2	(in	which	log2(FC)	=	0).	Y	axis	represents	log2(Fold	change),	equivalent	to	-ddCt	
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5.2.5 The presence of JARID1B is not required for FOXG1-induced activation 
of FoxO6 or Chd3 expression and Jarid1b loss alone is not sufficient to 
drive their activation 
In	parallel	to	assessing	colony	formation	on	induction	of	FOXG1	expression,	mRNA	
was	 collected	 to	 investigate	 whether	 JARID1B	 was	 required	 for	 transcriptional	
activation	 by	 FOXG1.	 In	 the	 Jarid1b-/-	 (+4OHT)	 cells	 with	 inducible	 FOXG1-V5	
overexpression,	an	upregulation	in	FoxO6	and	Chd3	levels	was	observed	on	addition	
of	Dox,	 indicating	 JARID1B	 is	not	 required	 for	FOXG1-induced	activation	of	 these	
genes	(Figure	5-8	A,	B	E	and	F).	 In	addition,	 Jarid1b	 loss	alone	does	not	result	 in	
FoxO6	or	Chd3	activation.		Again,	due	to	unequal	levels	of	FOXG1	transgene	expression	
we	could	not	make	any	firm	conclusions	regarding	the	relative	effects	of	Jarid1b	loss	on	
activation	 of	 these	 targets.	 However,	 the	 first	 experimental	 replicate,	 which	 showed	
evidence	of	equal	transgene	induction	in	both	cell	types	(Figure	5-7	A	and	B),	suggests	








































in	 Jarid1bF/F	 (-4OHT)	 cells	 in	 EGF/FGF-2	 -Dox	 (in	which	 log2(FC)	 =	 0).	 n=4	 independent	
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5.2.6 Available FOXG1 antibodies are sub-optimal for immunoprecipitation 
Following	the	derivation	of	additional	FOXG1	knock-out	mouse	and	human	GBM	model	
cell	lines,	described	in	sections	4.2.3	and	4.2.6,	we	decided	to	validate	the	co-IP	of	FOXG1	
and	 JARID1B	 using	 these	 as	 additional	 negative	 controls.	 Although	 isotype	 controls	
matching	the	class	and	type	of	the	primary	antibody	used	for	IP	are	standard	practice,	
knockout	 cell	 lines	 provide	 the	 most	 robust	 negative	 control,	 as	 any	 background	





input	 lane	 for	 each	 parental	 cell	 line,	 with	 no	 FOXG1	 expression	 in	 the	 null	 control.	







previous	 result	was	not	due	 to	non-specificity	 of	 the	Novus	Biologicals	 anti-JARID1B	
antibody.	 The	 IgG	 control	 showed	 no	non-specific	 binding	 by	 the	 beads	 or	 antibody,	
other	than	bands	we	considered	to	be	degradation	products	of	the	antibody	itself.	For	
example,	a	band	at	approximately	90	kDa	was	visible	in	all	IPs	(IgG	and	17B12)	which	
could	 be	 due	 to	 incomplete	 antibody	 denaturation.	 If	 due	 to	 unspecific	 binding,	 this	









raised	 against	 also	 leads	 to	 binding	 to	 another	Forkhead	 factor	which	 interacts	with	
JARID1B.	As	the	specific	epitope	sequence	is	not	available,	we	were	unable	to	formally	
test	this	hypothesis.		





down	 of	 FOXG1	 but	 poor	 enrichment	 compared	 to	 the	 input	 lane,	 and	 no	 co-IP	with	











null	 clonal	 line	 42.	 Blots	 probed	 with	 FOXG1	 17B12	 and	 anti-JARID1B	 antibodies	 (Novus	
Biologicals,	NBP1-84352).	(B)	 	17B12	FOXG1	 IP	 in	mouse	GSC	 line	 IENS	and	 IENS	Foxg1	null	
clonal	line	58	(all	cells	IENS-GFP).	Blots	probed	with	FOXG1	17B12	and	anti-JARID1B	antibodies	
(Novus	Biologicals,	NBP1-84352	and	DAIN78	(Helin	lab)).	(C)	17B12	FOXG1	IP	in	human	GNS	cell	
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5.3 CRISPR/Cas9-mediated gene tagging as a tool to aid 
exploration of protein-protein interactions 
The	 results	 in	 section	 5.2.6	 highlight	 the	 difficulties	 with	 reliance	 on	 native	
antibodies	 for	applications	such	as	 immunoprecipitation.	Our	results	 show	that	
isotype	 controls	 are	 not	 always	 sufficient	 to	 guarantee	 the	 specificity	 of	 an	
antibody.	 The	 advent	 of	 CRISPR/Cas9	 technology	 has	 meant	 the	 derivation	 of	
knockout	controls	has	become	more	accessible,	but	these	may	not	be	available	for	
every	protein	of	interest.	In	addition,	it	is	time-consuming	and	costly	to	search	for	
commercial	 antibodies	 suitable	 for	 each	 desired	 application	 and	 polyclonal	
antibodies	can	show	batch-to-batch	variation.	






Previously,	 epitope	 tagging	 in	 mammalian	 cell	 lines	 was	 limited	 to	 transgenes	






modified	 to	 incorporate	 a	 modified	 two-part	 synthetic	 cr/tracrRNA	 system	
(Dewari	et	al,	2018),	with	further	gains	in	efficiency.	
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5.3.1 Epitope tagging Foxg1 with a V5 tag in mouse and human GNS cells 
Highly	efficient	epitope	tagging	of	endogenous	genes	in	NS	cells	can	be	achieved	
without	 the	requirement	of	 selectable	markers,	 cell	 sorting	or	plasmid	delivery	
(Dewari	et	al,	2018).	These	studies	included	the	V5	tag,	a	42	bp	epitope	derived	
from	the	paramyxovirus	of	the	simian	virus	5	family.	This	is	a	widely	used	epitope	
tag	 in	 our	 laboratory	 and	 does	 not	 impair	 the	 production	 of	 functional	 FOXG1	





UTR	 of	 Foxg1,	 with	 minimal	 predicted	 off-target	 cleavage.	 Tagging	 at	 the	 C	
terminus	was	chosen	to	avoid	disruption	of	the	endogenous	gene-coding	sequence	
by	gRNA	cutting.	A	two-part	RNA	complex	was	then	formed	by	annealing	this	short,	
chemically	 synthesised,	 target-specific	 crRNA	with	 a	 longer	 universal	 tracrRNA	
(Anderson	et	al,	2015;	Jacobi	et	al,	2017)	(Figure	5-10	A).	This	dual	cr/tracrRNA	
(obtained	 from	 IDT)	 was	 then	 incubated	 with	 rCas9	 protein	 to	 form	 a	 Cas9	
ribonucleoprotein	 complex	 (RNP).	 This	 pre-assembled	 Cas9	 RNP	was	 then	 co-
delivered	 into	 cells	 alongside	 a	 single-stranded	 ~200	 bp	 long	





directly	 upstream	 of	 the	 stop	 codon	 (Figure	 5-10	 B).	 The	 bulk	 transfected	



































































FOXG1-V5	 tagging.	 Number	 indicates	 approximate	 tagging	 efficiency.	 Scale	 bar:	 100	 µm.	 (E)	
Sanger	sequencing	of	G7	and	G328	at	region	of	the	FOXG1	gene	around	the	gRNA	cutting	site.	
Regions	 of	 interest	 are	 highlighted,	 including	 FOXG1	 exon	 sequence	 (purple),	 STOP	 codon	
(orange),	PAM	site	(red),	gRNA	annealing	site	(yellow)	and	FOXG1	3’	UTR	(pink).	A-C	performed	
by	C.	Blin	and	S.	VijayKumar.	D-E	performed	by	S.	VijayKumar. 
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of	 the	 FOXG1	 protein,	 the	 p2A	 peptide	would	 be	 cleaved,	 leaving	 the	 C-terminal	
epitope	tag	and	a	small	portion	of	the	p2A	peptide	at	the	C	terminus	of	FOXG1.	The	
fluorescent	 eGFP	 tag	 would	 be	 released,	 leading	 to	 all	 cells	 with	 successful	 tag	
insertion	being	marked	by	positive	eGFP	expression.		
Following	a	report	that	dual	tagging	with	3xFLAG	and	HA	achieves	the	highest	IP	
efficiency	 (direct	 communication	 Olivier	 Ayrault,	 (Forget	 et	 al,	 2014)),	 a	 gene	
fragment	was	ordered	from	GeneArt,	which	was	sequence	verified	and	cloned	into	a	
pMX	series	vector	(Figure	5-13	A).	This	gene	fragment	consisted	of	the	3xFLAG-HA-p2A-
eGFP	 tag	 (with	 the	 FLAG	and	HA	 tags	 preceded	 by	 a	 GS	 linker	 and	 the	 p2A	 peptide	
preceded	by	a	GSG	 linker),	 flanked	by	500	bp	homology	arms.	These	homology	arms	






















HA-IPs	 using	 these	 sorted	 populations	 confirmed	 successful	 pull-down	 of	 the	 tagged	
FOXG1	protein	 in	both	G7	and	G313	(Figure	5-14).	As	expected,	 in	 the	 tagged	sorted	
populations,	the	input	lane	shows	two	bands	for	FOXG1,	at	approximately	70	and	76	kDa;	
this	 indicated	 remaining	 untagged	 FOXG1	 protein	 due	 to	 the	 presence	 of	 a	 mixed	
population	of	heterozygous	or	homozygous	tagged	cells.	Tagged-FOXG1	was	modestly	



















































































therefore	 considered	 the	 FOXG1-JARID1B	 interacting	 regions	 would	 most	 likely	 be	
conserved	 between	 mouse	 and	 human	 proteins.	 Deletion	 of	 Jarid1b	 was	 previously	
shown	to	have	no	effect	on	the	expression	of	other	Jarid1-family	members	(Schmitz	et	al,	
2011);	 furthermore	 while	 JARID1	 proteins	 show	 high	 sequence	 homology,	 domain	
differences	in	their	C	terminals	are	thought	to	lead	to	the	formation	of	diverse	protein	
complexes,	 with	 only	 JARID1B	 reported	 to	 bind	 to	 FOXG1	 (Catchpole	 et	 al,	 2011).		
Therefore,	 we	 also	 considered	 it	 unlikely	 that	 loss	 of	 Jarid1b	would	 be	 replaced	 by	
redundant	functions	of	other	Jarid1	members.	Based	on	our	validation	that	full-length	
JARID1B	 expression	 is	 absent	 at	 the	mRNA	 and	protein	 level	 in	+4OHT	 treated	 cells	
(Figure	5-3	E	and	F)	and	previous	validation	of	this	deletion	strategy	by	Schmitz	et	al.,	
we	reasoned	these	cells	could	be	termed	Jarid1b-/-.	Due	to	the	lack	of	available	antibodies	
against	 the	 N-terminus	 of	 JARID1B	 it	 was	 not	 possible	 to	 confirm	 the	 absence	 of	










While	we	 cannot	 exclude	 a	 role	 of	 a	 FOXG1-JARID1B	 interaction	 in	 activation	or	
repression	 of	 other	 genes,	 the	 ability	 of	 FOXG1	 overexpression	 to	 drive	 a	
proliferative	NS	cell-like	state	 in	the	absence	of	 JARID1B	suggests	that	any	genes	
regulated	via	FOXG1-JARID1B	are	not	determining	factors	of	this	cell	fate	transition.	
In	 addition,	 the	 loss	 of	 JARID1B	 alone	 was	 not	 sufficient	 to	 drive	 cells	 into	 a	
proliferative	state	or	lead	to	upregulation	of	FoxO6	or	Chd3	(Figures	5-6,	5-7	and	5-





JARID1B	 loss	 itself	 did	 not	 significantly	 affect	 NSC	 proliferation	 in	 EGF/FGF-2	
(Figure	5-4)	or	response	to	BMP4	signalling	(Figure	5-5).	Indeed,	while	JARID1B	is	
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BMP4.	 However	 again,	 the	 lack	 of	 markers	 to	 distinguish	 cell	 states	 along	 the	





induced	colony	 formation,	as	hinted	by	our	 initial	 replicate	 (Figure	5-7	A-C).	We	
therefore	cannot	rule	out	a	contributing	factor	of	JARID1B	in	increasing	efficiency	of	
FOXG1-induced	 colony	 formation,	 irrespective	 of	 FoxO6	 and	 Chd3,	 and	 further	
exploration	is	needed.		
Although	 the	 unequal	 levels	 of	 FOXG1	 transgene	 induction	 hampered	 our	
conclusions,	this	was	accompanied	by	an	interesting	observation.	Despite	an	~25-
fold	upregulation	in	FOXG1	mRNA	expression	in	 Jarid1bF/F	(-4OHT)	cells	in	Dox,	NS	























co-IP	 could	 reveal	 if	 FOXG1	 is	pulled	down	with	 JARID1B.	 It	 is	also	plausible	 that	an	
alternative	 buffer	 composition	 is	 needed	 to	 capture	 this	 interaction;	 a	 mild	 non-









We	 performed	 native	 IPs	 to	 enable	 us	 to	 observe	 interactions	 relevant	 to	 both	DNA	
binding-dependent	and	-independent	functions	of	FOXG1.	However,	FOXG1’s	interaction	





TFs	 in	 GNS	 cells	 using	 RIME	 (Rapid	 Immunoprecipitation	 Mass-spectrometry	 of	
Endogenous	proteins)	(Mohammed	et	al,	2013,	2016).	This	protocol	involves	an	initial	
two-step	 crosslinking	 procedure	 using	 disuccinimidyl	 glutarate	 and	 formaldehyde	 to	
conserve	both	protein-DNA	and	protein-protein	interactions	(Papachristou	et	al,	2018;	







Here,	 we	 show	 how	 this	 method	 can	 be	 modified	 to	 account	 for	 variable	 HDR	
efficiencies	 in	 different	 GNS	 cell	 lines	 (Figure	 5-12	 D),	 by	 introduction	 of	 a	 self-
cleaving	fluorescent	tag	(Figure	5-13).	This	strategy	could	be	used	in	multiple	cell	lines,	
independent	of	HDR	efficiency,	to	derive	sorted	populations	with	a	high	proportion	of	
tagged	 cells.	 To	 increase	 the	 efficiency	 of	 FOXG1	 bait	 enrichment,	 the	 use	 of	
sequential	FLAG/HA	tandem	affinity	purification	should	be	explored	(Forget	et	al,	
2014).	Use	of	‘bulk’	sorted	populations	in	downstream	IPs	would	allow	the	cellular	
heterogeneity	 to	 be	 conserved	 as	 is	 present	 in	 the	 tumour;	 this	 avoids	 the	 risks	
associated	with	clonalisation,	which	 is	particularly	problematic	 in	heterogeneous	
cultures	 such	 as	 patient-derived	GNS	 cell	 lines.	Alternatively,	multiple	 clonal	 cell	
lines	 could	 be	 efficiently	 derived	 from	 the	 sorted	 population	 and	 validated	 for	
homozygous	tag	insertion.	FOXG1	expression	was	shown	by	ICC	to	be	unaltered	by	








In	 conclusion,	 in	 this	 chapter	 we	 have	 found	 that	 JARID1B	 is	 not	 required	 for	
FOXG1’s	 functions	 in	 driving	 a	 proliferative	NS	 cell-like	 state	 and	 transcriptional	
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CHAPTER 6  
General Discussion 
In	this	thesis	we	present	work	that	improves	our	understanding	of	the	key	downstream	
transcriptional	 targets	 and	 protein	 interactions	 of	 FOXG1	 in	 GBM.	 In	 this	 General	
Discussion	 I	 will	 discuss	 the	 key	 themes	 highlighted	 by	 our	 findings	 and	 current	
conclusions,	and	how	these	relate	 to	 the	current	 literature.	Within	each	section	 I	will	
highlight	areas	of	future	research.	
6.1 FOXG1 drives an NS cell identity through transcriptional control 
of cell cycle and epigenetic regulators 
FOXG1	 is	 widely	 known	 for	 its	 roles	 in	 brain	 development,	 with	 functional	 roles	
including	 control	 of	 neural	 progenitor	 proliferation	 and	 differentiation,	 ventral	
















previously	 identified	by	our	 lab	 to	be	both	bound	by	 and	transcriptionally	 altered	 in	
response	 to	 overexpression	 of	 FOXG1/SOX2	 human	 transgenes	 (Figure	 3-1).	 This	







DNA-independent	 interactions,	 FOXG1	 directly	 activates	 the	 transcription	 of	 genes	
controlling	the	cell	cycle.	Further	work	is	needed	to	explore	FOXG1’s	regulation	of	cell	
cycle	inhibitors,	such	as	p21	and	p27	in	this	context.	




overexpression	 and	 therefore	may	 contribute	 to	 FOXG1-induced	 epigenetic	 resetting	
(Figure	 3-9).	 RRBS	 analysis	 of	 cells	 before	 and	 after	 BMP4	 treatment	 revealed	
significantly	DMRs	in	the	vicinity	of	developmental	PRC	target	genes,	 including	near	a	
FOXG1	 binding	 site	 at	 the	 promoter	 of	 FoxO3	 (Figures	 3-10,	 3-11	 and	 3-12).	While	
directions	of	transcriptional	change	are	difficult	to	predict	based	on	acquisition	or	loss	
of	 DNA	 methylation,	 these	 results	 suggest	 that	 high	 FOXG1	 levels	 reconfigure	 DNA	
methylation	 patterns	 to	 a	 stem-like	 state	 through	 transcriptional	 activation	 of	 DNA	
methylation	regulators.	FOXG1	therefore	drives	an	NS	cell	identity	both	through	driving	





cell	 proliferation	 and	neural	 cell	 fate	 in	development	 and	 cancer.	 For	 example,	while	
overexpression	of	 the	cell	cycle	 inhibitor	p27xic1	 in	Xenopus	embryos	was	sufficient	 to	
inhibit	proliferation	of	neuroectodermal	cells,	it	did	not	fully	recapitulate	the	effects	that	










al,	 2013).	 Our	 results	 are	 in	 fitting	 with	 FOXG1	 driving	 changes	 in	 the	 epigenetic	
landscape	that	facilitate	the	acquisition	of	a	proliferative	radial	glia-like	NSC	phenotype.		




but	 maintaining	 the	 GSC	 state.	 Indeed,	 overexpression	 of	 developmental	 master	
regulators	 in	 GNS	 cell	 lines	 has	 been	 suggested	 to	 restrict	 their	 differentiation	
commitment	 by	 inhibiting	 appropriate	 chromatin	 remodelling	 at	 gene	 regulatory	
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regions;	 for	 example	 analysis	 of	 the	 chromatin	 regions	 that	 failed	 to	 close	 on	 BMP4	
treatment	 of	 GNS	 cells	 revealed	 an	 enrichment	 in	 developmental	 TF	 binding	motifs,	
including	 Forkhead	 factors	 (Carén	 et	 al,	 2015).	 Furthermore,	 ATAC-seq	 analysis	
performed	by	 the	Pollard	 lab	 in	GNS	and	NS	 cells	suggested	FOXG1	 target	 genes	 are	
persistently	 ‘open’	 in	 the	 GNS	 cell	 state.	 High	 FOXG1	 levels	 in	 GSCs	 may	 therefore	
regulate	the	expression	of	chromatin	remodellers,	such	as	Chd3,	which	in	turn	ensure	an	
open	 chromatin	 landscape	 to	 enable	FOXG1	 binding	 to	 regulatory	 elements.	 Another	
NuRD	component,	Chd4,	has	been	shown	to	modulate	GSC	gene	expression	directed	by	
the	TF	ZFHX4	(Chudnovsky	et	al,	2014).	
We	 note,	 however,	 that	we	 did	not	 observe	 a	 significant	 correlation	 between	FOXG1	
levels	 and	 CHD3,	 nor	 FOXO6,	 expression	 in	 patient-derived	 GNS	 cell	 lines	 or	 tissue	
samples	(Figures	4-12	and	4-16).	The	tissue	samples	in	these	studies	however	do	not	
capture	the	GSC	population	alone	and	the	GNS	cell	lines	were	cultured	in	EGF/FGF-2.	We	




‘differentiated’	GNS	cells	 that	are	growth	 factor	unresponsive.	Such	 conditions	would	
assist	 us	 in	 determining	 whether	 GNS	 cells	 are	 more	 susceptible	 to	 serum-induced	
differentiation	and/or	re-entry	into	cell	cycle	on	misexpression	of	FOXG1/FOXO6/CHD3.		
6.2 FoxO6 is a transcriptional target of FOXG1 
Our	studies	identified	the	Forkhead	factor	FoxO6	as	a	key	target	downstream	of	FOXG1.	
Although	 the	 least	well-studied	of	 the	FoxO	 factors,	 a	number	of	 recent	 studies	have	





difficult	 to	 drug,	 delineating	 the	 role	 of	 FoxO6	 with	 respect	 to	 controlling	 the	
proliferation,	differentiation	and	metabolism	of	GSCs	may	further	our	understanding	of	
the	 processes	 underlying	 GSC	 self-renewal	 and	 exit	 from	 quiescence.	 While	 the	
downstream	targets	of	FoxO6	in	NS	cells	are	unknown,	FoxO6	has	been	implicated	in	
leading	to	transcriptional	changes	in	various	cell	contexts.	For	example,	analysis	of	the	
genes	 downregulated	 in	 hippocampal	neurons	 of	FoxO6	 null	mice	 following	 learning	
experiments	 identified	 p53	 pathway	 genes	 and	 a	 co-occurrence	 of	 binding	 sites	 for	










competition	 exist	 in	 GSCs,	whereby	 FOXG1	 acts	 to	 antagonise	 FOXO3,	which	 in	 turn	
antagonises	FOXO6?	Several	Forkhead	factors	have	been	shown	to	act	antagonistically;	
for	 example	 FOXO3	 antagonises	 FOXM1	 transcriptional	 activity	 through	 several	
mechanisms	(Lam	&	Gomes,	2014).	FOXG1	itself	has	been	shown	to	sequester	FOXO1/3-
SMAD	complexes	as	well	as	directly	repress	FoxO1/3	expression	in	neural	progenitors	
(Vezzali	 et	 al,	 2016;	 Bulstrode	 et	 al,	 2017).	 Furthermore,	 at	 a	 later	 stage	 of	 cortical	















6.3 FOXG1 can act as a transcriptional activator and repressor 
In	 contrast	 to	 FoxO3,	 which	 is	 downregulated	 in	 response	 to	 elevated	 FOXG1	 levels	




from	 studies	 of	 neurogenesis	 patterning	 in	 the	Xenopus	 ectoderm;	while	 injection	 of	
FoxG1	 RNA	 fused	 to	 a	 repressor	 domain	 mimicked	 most	 the	 wild-type	 functions,	
suppression	of	endogenous	levels	of	the	neuron	marker	N-Tubulin,	was	only	achieved	
when	FoxG1	was	fused	to	an	activator	domain.	This	suggested	that	while	predominantly	
repressive,	 high	 FOXG1	 levels	 also	 have	 some	 activating	 functions	 in	 inhibiting	
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controls	 neocortical	 projection	 neuron	 production	 in	 the	 cerebral	 cortex	 of	 mice	
revealed	 several	 immediately	 upregulated	 transcripts	 amongst	 a	 predominantly	
repressive	transcriptional	programme	(Kumamoto	2013).	FOXG1	overexpression	in	rat	
hippocampal	neural	precursor	cells	also	showed	an	immediate	upregulation	of	several	
transcripts	 (Nam	 et	 al,	 2010).	 Furthermore,	 Dali	 et	 al	 found	 that	 89%	 of	 the	 150	
differentially	expressed	genes	identified	upon	FOXG1	deletion	in	GSCs	were	upregulated,	
indicating	the	remaining	11%	are	activated	targets	of	FOXG1.	Together	with	our	findings,	
there	 is	 evidence	 to	 support	 an	 under-explored	 role	 of	 FOXG1	 as	 an	 activator	 of	
transcription.		
How	does	FOXG1	achieve	this	activation?	Forkhead	factors	are	known	to	display	diverse	
regulatory	properties	 owing	 to	 their	differences	 in	 tissue-specific	 expression,	 protein	
domains,	protein-protein	interactions	and	PTMs.	While	they	generally	act	as	activators	
or	 repressors	 of	 gene	 expression,	 it	 is	 therefore	 possible	 that	 they	 act	 in	 a	 context-
dependent	manner	through	modification	of	these	features.	For	example,	co-activators	or	
co-repressors	may	bind	to	a	TF	in	different	cellular	contexts,	for	example	dependent	on	
the	 phosphorylation	 status	 of	 the	 TF.	 Examples	 of	 context-dependent	 functions	 exist	
within	the	Forkhead	family,	with	FoxP1	reported	to	have	tumour	suppressive	functions	
in	 some	 types	 of	 cancer	 but	 oncogenic	 roles	 in	 B	 cell	 lymphoma,	 possibly	 owing	 to	
transactivation	of	genes	involved	in	B	cell	development	(Fox	et	al,	2008;	Aster	&	Kutok,	
2009;	Hu	et	al,	2006).	Within	individual	cells,	the	TF	GATA-1	has	been	shown	to	form	







could	 recruit	 co-activators	 or	 that	 elevated	 FOXG1	 levels	 could	 act	 to	 sequester	 the	








sequester	 a	protein	partner	preventing	 transcriptional	 co-repression,	 is	an	appealing	
hypothesis	 for	 further	 investigation	 (Figure	 5-1	 B).	 FOXG1	 has	 known	 DNA-binding	
independent	 functions	 through	which	 it	 indirectly	 leads	 to	 transcriptional	 repression	
(Hanashima	et	al,	2002;	Seoane	et	al,	2004;	Li	et	al,	2013),	therefore	it	is	plausible	that	




several	 studies	 indicate	 a	 concentration-dependent	 mechanism	 of	 action	 of	 FOXG1	
(Bourguignon	 et	 al,	 1998;	 Hardcastle	 &	 Papalopulu,	 2000;	 Shen	 et	 al,	 2006).	
Furthermore,	while	 further	 exploration	 is	needed,	 from	our	data	we	 speculate	 that	a	
FOXG1	threshold	may	exist	above	which	activation	of	FoxO6/	Chd3	expression	occurs.		
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binding	 to	 TCF/LEF	 and	 enabling	 Wnt	 target	 transcription.	 We	 are	 currently	
investigating	 whether	 FoxO6	 is	 a	 Wnt	 target	 gene;	 initial	 experiments	 suggest	 that	
indeed,	 FoxO6	 may	 be	 activated	 by	 Chiron	 (a	 small	 molecule	 stimulator	 of	 Wnt	
signalling).	Following	this	we	would,	in	future,	like	to	investigate	the	effect	of	deleting	









lead	 to	 a	 switch	 in	 activity	 by	 facilitating	 dimerisation;	 for	 example	 Krüppel	 acts	
bimodally	as	a	monomer	 and	dimer	 through	different	 interactions	with	 transcription	
initiation	 factors	 (Sauer	 &	 Jackie,	 1991;	 Sauer	 et	 al,	 1995)	 and	 homo-	 or	
heterodimerisation	 of	 FoxP1	with	FoxP2/4	 is	 required	 for	 co-factor	 interactions	 and	
transcriptional	repression	(Li	et	al,	2004).	A	concentration-dependent	basis	of	FOXG1’s	
transcriptional	activities	is	clearly	of	interest	for	further	exploration	in	GSCs.	
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6.4 Defining the key protein partners important to FOXG1’s 










as	 Chd3,	 also	 exist	 as	 protein	 partners.	 Another	 reprogramming	 transcription	 factor	





FOXG1	 in	 multiple	 patient-derived	 GNS	 cell	 lines	 (Figure	 5-13).	 This	 opens	 up	
possibilities	for	performing	downstream	protein-protein	interaction	studies	to	further	
decipher	FOXG1’s	interactome.	This	methodology	could	be	further	used	to	tag	FOXG1	in	
non-tumorigenic	human	 foetal	NS	 cell	 lines,	 enabling	 comparison	of	 FOXG1’s	protein	
partners	in	a	normal	versus	malignant	state	by	IP-Mass	spectrometry.	Furthermore,	this	
technology	 could	 be	 used	 to	 iteratively	 tag	 and	 validate	 subsequently	 identified	
candidate	 protein	 interactors	 without	 the	 reliance	 on	 good	 quality	 protein-specific	
antibodies.	This	would	enable	the	use	of	a	single	antibody	in	protein	analysis	studies	of	















spots	 (Frank,	 2002;	 Kramer	 and	 Schneider-Mergener,	 1998).	 Key	 amino	 acids	 or	 a	
minimal	binding	sequence	can	be	further	identified	by	alanine	scanning	or	N/C	terminus	
truncation,	and	cell-permeable	protein-protein	interaction	disruptor	(PPID)	peptides	or	
small	 molecules	 can	 be	 synthesised	 and	 screened	 for	 their	 ability	 to	 block	 the	 PPI.	
Numerous	 PPIDs	 have	 been	 published	 and	 several	 have	 entered	 clinical	 trials,	
highlighting	the	possibility	of	targeting	PPIs	to	treat		diseases	including	cancer	(Ivanov	
et	al,	2014;	Mabonga	&	Kappo,	2020).	 
6.5 Concluding remarks 
GBM	is	a	currently	incurable,	aggressive	adult	brain	tumour,	thought	to	be	driven	by	a	
population	of	NS	cell-like	GSCs.	There	 is	an	urgent	need	 for	new	treatments	to	 target	
these	 cells	 and	 prevent	 patient	 relapse	 following	 surgery	 and	 chemo/radiotherapy.	
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I. CRISPR gRNA sequences 
II. CRISPR donor DNA sequences 
Target	
gene	 Purpose	 Sequence	(5’	to	3’)	 PAM	 Species	
Additional	
ID	
FoxO6	 Gene-tagging	 GGCACCCAGGCTGTGTAGGG	 TGG	 Mouse	 2	
Foxg1	 Gene-tagging	 TTTAATACATTAACATCCGG	 GGG	 Mouse	 M85	
FOXG1	 Gene-tagging	 TCACTTACAGTCTGGTCCCA	 GGG	 Human	 2	


















































































































pCMV-pBase	 Ampicillin	 N/A	 sp59	
















































































ANS4	 Mouse	 Parental	 N/A	
Derived	from	SVZ	of	
adult	mouse	



















































G301-B	 Human	 Parental	 N/A	 Patient-derived	GNS	cell	line	from	GCGR.	
G317	 Human	 Parental	 N/A	 Patient-derived	GNS	cell	line	from	GCGR.	
 
 229 
G325	 Human	 Parental	 N/A	
Patient-derived	GNS	
cell	line	from	GCGR.	
G326	 Human	 Parental	 N/A	 Patient-derived	GNS	cell	line	from	GCGR.	
G327	 Human	 Parental	 N/A	 Patient-derived	GNS	cell	line	from	GCGR.	
G328	 Human	 Parental	 N/A	 Patient-derived	GNS	cell	line	from	GCGR.	
G330	 Human	 Parental	 N/A	 Patient-derived	GNS	
cell	line	from	GCGR.	
CB152	 Human	 Parental	 N/A	
Human	foetal	NS	cell	
line.	
















































































































Application	 Dilution	 Manufacturer	 Catalogue	
V5	tag	 Mouse		IgG2b	 WB/	ICC	 1:1000/1:2000	 eBioscience	 14-6796	
GFAP	 Rabbit	IgG	 ICC	 1:1000	 Sigma	 G9269	
GFAP	 Mouse	 ICC	 1:1000	 Sigma	 G3893	









polyclonal	 IP	 10	µg	per	IP	 Abcam	 ab18259	
Gapdh	 Mouse	IgG2b	 WB	 1:1000	 GenTex	 GTX627408	
Olig2	 Rabbit	IgG	
polyclonal	
ICC	 1:300	 Millipore	 ab9610	
Sox2	 Rabbit	IgG	
polyclonal	
ICC	 1:100	 Abcam	 ab92492	
Tuj1	 Mouse	IgG2a	 ICC	 1:1000	 Biolegend	 801202	
Blbp	 Rabbit	IgG	
polyclonal	
ICC	 1:200	 Santa	Cruz	 sc30088	
Jarid1b	 Rabbit	IgG	
polyclonal	
WB	 1:1000	 Novus	Biologicals	 NBP1-84352	
Jarid1b	 Rabbit	IgG	
polyclonal	






Ki67	 Rabbit	IgG	 ICC	 1:200	 Thermo	Fisher	 RB-9043-P0	
FLAG	 Mouse	IgG1	monoclonal	 ICC	 1:2000	 Sigma	 F3165	
HA	 Mouse	IgG1	monoclonal	 WB/	ICC	 1:1000/1:100	
Cell	Signaling	
Technology	 (6E2)	2367	
HA	 Mouse	 IP	 5	µg	/	IP	 Abcam	 ab9110	
Mouse	IgG	
From	mouse	
serum	 IP	 10	µg	/	IP	 Sigma	 I5381	
Antigen	 Species	and	Isotype	 Application	 Dilution	 Conjugation	 Manufacturer	
Various	












Goat	 WB	 1:10000	 HRP-linked	 GE	
 
 231 






















































































VII. TaqMan assays 
Gene	 Species	 Dye	 Order	number	
Gapdh	 Mouse	 FAM-MGB	 Mm99999915_g1	
FOXG1	 Human	 FAM-MGB	 Hs01850784_s1	
Foxo6	 Mouse	 FAM-MGB	 Mm00809934_s1	
Foxo3	 Mouse	 FAM-MGB	 Mm01185722_m1	
NMyc	 Mouse	 FAM-MGB	 Mm00476449_m1	
Plk1	 Mouse	 FAM-MGB	 Mm00440924_g1 
Chd3	 Mouse	 FAM-MGB Mm01332658_m1 
Tet3	 Mouse	 FAM-MGB Mm00805756_m1 
Dnmt1	 Mouse	 FAM-MGB Mm01151063_m1 
Dnmt3b	 Mouse	 FAM-MGB Mm01240113_m1 
Dnmt3a	 Mouse	 FAM-MGB	 Mm00432881_m1	
Hdac7	 Mouse	 FAM-MGB Mm00469527_m1 
Ezh2	 Mouse	 FAM-MGB Mm00468464_m1 
Nestin	 Mouse	 FAM-MGB Mm00450205_m1 
Blbp	(Fabp7)	 Mouse	 FAM-MGB Mm00445225_m1 
Olig2	 Mouse	 FAM-MGB	 Mm01210556_m1	
Aqp4	 Mouse	 FAM-MGB	 Mm00802131_m1	
S100	 Mouse	 FAM-MGB	 Mm00485897_m1	
Gfap	 Mouse	 FAM-MGB	 Mm01253033_m1	
FOXO6	 Human	 FAM-MGB	 Hs01010449_s1	
CHD3	 Human	 FAM-MGB	 Hs01050212_m1	





VIII. Supplementary RNA-seq data  

















































































































































































































Original GNS cell line names and new GCGR names 
 
 
 
 
 
Original	
name	 GCGR	name	
G301B	 GCGR-E1	
G303B	 GCGR-E3	
G304B	 GCGR-E4	
G313	 GCGR-E13	
G315	 GCGR-E15	
G317	 GCGR-E17	
G322	 GCGR-E22	
G326	 GCGR-E26	
G327	 GCGR-E27	
G328	 GCGR-E28	
G318	 GCGR-E18	
G320	 GCGR-E20	
G321	 GCGR-E21	
Original	
name	 GCGR	name	
G324	 GCGR-E24	
G325	 GCGR-E25	
G330	 GCGR-E30	
G335	 GCGR-E35	
G331	 GCGR-E31	
G334	 GCGR-E34	
G337	 GCGR-E37	
G339	 GCGR-E39	
G343	 GCGR-E43	
G351	 GCGR-E51	
G353	 GCGR-E53	
G354	 GCGR-E54	
G355	 GCGR-E55	
